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ABSTRACT
Biotherapeutics have revolutionized medicine with their ability to achieve
unprecedented molecular recognition and mediate complex biological responses.
The intracellular delivery of biotherapeutics is an unmet scientific challenge and
medical need. A wide variety of different treatment modalities depend on not only
on the ability to achieve intracellular delivery, but to do so in a targeted manner.
An independently-targeted, two-molecule system was developed to
accomplish intracellular delivery in a uniquely specific manner. Immunotoxins
were designed based on the plant toxin gelonin and targeted towards the canonical
cancer-specific antigens: epidermal growth factor receptor and carcinoembryonic
antigen. Using quantitative internalization flow cytometry matched with controlled
exposure cytotoxicity, the number of internalized gelonin immunotoxins required to
induce apoptosis in a single cell was found to be -5x10 6 molecules. This threshold
to cytotoxicity was conserved across all gelonin constructs regardless of antigen
target, binding scaffold, affinity, or cell line. Next, cholesterol-dependent cytolysins
were targeted to the same antigens by genetic fusion to engineered fibronectin
domains. When combined in vitro, targeted gelonin and cytolysin had synergistic
cytotoxic effects and the presence of cytolysin reduced the intracellular barrier to
cytotoxicity to < 104 immunotoxin molecules. In vivo, these molecules induced non-
specific, dose-limiting toxicities at varying levels and were cleared from the plasma
at rates consistent with their molecular weight. Dosed individually, neither
compound was capable of controlling tumor xenografts, but when combined in a
delayed dosing scheme they inhibited tumor growth and induced apoptosis
throughout xenografts as confirmed by histology. Mathematical modeling was
informed by in vivo experiments and provided insight in dosing and tumor exposure
overlap.
These results emphasize the necessity of a targeted intracellular delivery
system and support the merit of the described approach. Additional research into
the safety and efficacy of these molecules as well as the design of new constructs
will certainly improve the clinical relevance of this technique.
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Chapter 1 - Intracellular delivery of biotherapeutics
1.1 - The biotechnology revolution and biotherapeutics
The pharmaceutical industry is in the process of undergoing a radical change in not
only their business models but in the way they conduct research and development.
In the second half of the 20th century, these companies reaped the rewards of
advances in organic chemistry processes and small molecule therapeutics. But in
recent years the small molecule well has gone relatively dry and the rise of
biotechnology has led to the development of a new class of therapeutics synthesized
biologically. These biotherapeutics represented a significant fraction (~30%) of the
drugs approved in 2010 (1). It seems likely that biologics will continue to take a
greater share of Food and Drug Administration approvals each year in the future as
pharmaceutical companies shift their research foci towards this area through
mergers, acquisitions, and restructuring.
Antibodies are the most prevalent biotherapeutics in use today with 32
approved drugs for a variety of indications (2). In their IgG format, antibodies
exists as 150 kDa proteins with specific bivalent binding to an antigen target
(Figure 1.1). Over the years, variations on this format have emerged: from Fab
(single binding arm) to scFv (variable regions connected by a linker) constructs.
And more recently smaller scaffolds such as fibronectin domains (3, 4), darpins (5,
6), and affibodies (7, 8) have been diversified and engineered to attain monovalent
antigen binding affinities equal to the bivalent avidity of early antibodies.
10
V W Figure 1.1 - Antibody structure.
H cThe structure of an IgG including
the heavy and light chains as
connected through inter-domain
disulfide bonds and their
hpt breakdown into variable and
constant domains. V = variable, C
= constant, XL = light chain, XH =
heavy chain (9).
Therapeutics targeted by molecular recognition, like antibodies, have been
medicine's closest realization of Paul Ehrlich's dream of a "magic bullet" to treat
disease (10). As antibody technologies matured, researchers began to investigate
various methods of enhancing their potency (Figure 1.2). Recent developments have
begun to build upon the basic IgG structure highlighted by the European Medicines
Agency approval of the first bispecific therapeutic Catumaxomab in 2009 (11) and
by numerous other multi-valents (12), antibody drug conjugates (13, 14), and
empowered antibodies (15, 16) in clinical and preclinical trials. The next generation
of targeted therapeutics will soon be broadly available in the clinic and making a
difference in the lives of patients. Another member of this category of targeted
therapeutics is immunotoxins, which combine an antibody fragment or other
antigen binding domain with a plant or bacterial toxin.
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a Enhancing effector d Pre-targeting
functions
Complement-dependent Biotin-chelator-
cytotoxicity radionuclide
Point mutations Streptavidin
and/or modified
glycosylation
Antibody-dependent Prodrug
cellular cytotoxicity 
scFv-enzyme
Tumnour cell Drug
Cytokine scFv
0 fragment
Immunocytokine
Stencally stabilized
Small molecule immunoliposomes
or protein toxin
Radionuclide Bispecitic
antbody Radionuclide, toxin
or immunological
effector cell
b Direct arming c Indirect arming
Figure 1.2 - Antibodies advanced. Antibodies can be adapted for increased efficacy
by (A) engineering effector functions, (B) fusing or conjugating to toxins, (C)
tangential modalities, or (D) primary/secondary approaches (9). This work begins
by developing a direct arming variant based on fibronectin domain targeting of a
protein toxin and goes on to develop something more akin to a pre-targeting
approach using a fibronectin targeted bacterial delivery protein as a secondary
agent.
1.2 - Immunotoxins
For over two decades, researchers have envisioned a highly effective immunotoxin
for cancer therapy (17). Initially, toxins were purified from their primary source,
either bacteria or plants, and conjugated to monoclonal antibodies using chemical
techniques. Thanks to the great diversity of evolution there is a wide array of
toxins to select from including type-I and type-II ribosome inactivating proteins
(RIPs), apoptosis inducers, and inhibitors of other cellular mechanisms. In addition
there are numerous antibodies and antibody fragments with specificity for a broad
12
selection of cancer specific antigens. Thus the possible combinations of toxin and
antibody are enormous and while researchers have investigated scores of
permutations, there are still many variations yet to be studied. Currently there has
only been one immunotoxin approved by the FDA: OntakTM (recombinant
interleukin-2/diphtheria toxin, Ligand Pharmaceuticals) (18). It is indicated for
treatment of cutaneous T-cell lymphoma.
The greatest successes in the use of immunotoxins have been achieved when
treating hematological cancers that avoid the transportation obstacles encountered
when targeting a solid tumor. There are currently more than a dozen
immunotoxins in clinical trials, most of which have failed to meet expectations (19),
but there is still evidence for successful treatment of solid tumors with
immunotoxins (20). In a tumor there are a myriad of barriers against
macromolecular access including non-uniform capillary distribution and blood flow,
high interstitial pressure, low diffusion constants, and antigen binding. Despite
these issues, free IgG has been used with success in the treatment of solid tumors,
as exemplified by the anti-ErbB2 drug Herceptin TM (21). Treatment in this manner
requires labeling of a cancer cell with enough antibodies to activate antibody-
dependent or complement-dependent cytotoxicity or enough to block signaling from
the ligand/antigen. These mechanisms often require significant antibody saturation
of the tumor. Since intoxication of a cancer cell involves only a few immunotoxin
molecules inside the cytoplasm, an ideal immunotoxin would require neither tumor
saturation nor the assistance of immune cells.
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Gelonin is a plant toxin found in the seeds of Gelonium multiflorum, native to
Asia. As a type-I RIP it contains no binding domain and likely evolved as an
apoptotic mechanism for infected plant cells that would store it in a vacuole. Like
all plant RIPs, gelonin is an RNA glycosidase that cleaves a specific adenine residue
from 28s rRNA. It does so with a catalytic efficiency such that only a few molecules
in the cytoplasm of a eukaryotic cell will inhibit protein synthesis to the point that
the cell initiates apoptosis. However, because gelonin is a type-I RIP and contains
neither binding nor translocation domains, it is non-toxic up to micromolar
extracellular concentrations. An approximately 30 kDa protein, gelonin was first
produced in a recombinant form in 1993 (22) allowing for simple insertion as a
fusion protein with antibodies. Researchers working with Dr. Michael Rosenblum
have previously used gelonin in immunotoxins with antibodies against melanoma
gp240 (ZME-018) (23, 24), anti-CD33 (M195) (25, 26), and histocompatibility
leukocyte antigen (Lym-1) (27). The properties of gelonin make it ideal for this
application since its conjugation has only a small effect on plasma half-life of free
antibody and its immunotoxins exhibit limited reticuloendothelial uptake. By
comparison, ricin A chain toxin-containing conjugates have significantly lowered
half-lives and elevated uptake in both the liver and spleen (28, 29). Ricin A chain
must be separated from the binding moiety for efficacy.
When treating cells with very high expression levels of an internalizing
antigen, immunotoxins with binding domains of moderate affinity may accumulate
in intracellular compartments at sufficient levels to facilitate stochastic
14
translocation of the few molecules needed to induce apoptosis. However, if an
antibody has too low affinity or, as may more often be the case, the target antigen is
not sufficiently over-expressed, then not enough immunotoxin will be internalized
and cytotoxicity will never be achieved. The choice of binding target and specific
binding affinity for that target are therefore important parameters that can
influence the in vivo toxicity and overall efficacy of an immunotoxin.
1.3 - Biotherapeutic intracellular delivery
A major challenge in the clinical application of many biotherapeutics is endosomal
escape: instead of entering the main body of a cell, the molecules become trapped in
isolated compartments called endosomes where they are eventually destroyed (30,
31). Fundamentally, it is the ability of the toxin to escape the endosomal
compartment holding it following internalization that ultimately determines the
potency of the immunotoxin. Because of the extreme efficiency of ribosome
inactivation, immunotoxins without a native translocation mechanism are ideal
tools for querying intracellular delivery. Advances in the design of proteins that
bind to disease-specific markers have given researchers the ability the send drugs to
the appropriate tissue and get inside the endosome, but for many therapeutics,
specifically those that are active only in the cytoplasm or nucleus, this is not
enough. Finding ways to enhance escape from endosomes in a targeted manner is
recognized as a central challenge not only for for type-I immunotoxins (32) but also
for siRNA and gene therapy (33, 34).
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Early developers of immunotoxins diverged in their use of different types of
toxins; those generally working with type II toxins such as diphtheria toxin, ricin, or
pseudomonas exotoxin didn't worry about intracellular delivery because these
toxins incorporate their own translocation mechanisms facilitating cytoplasmic
access (35-37). Others working with type I toxins such as gelonin or saponin
investigated various small molecule and protein based methods for enhancing
translocation with moderate success in vitro (38-43).
Many methods of achieving intracellular delivery of immunotoxins have been
tested (41), including small molecule potentiators (42, 44-46), proteins (47-49), and
peptides (50-52). These enhancers have shown mixed results, and are often limited
by immunogenicity or lack of potency. Of the different protein domains used to
affect intracellular delivery cholesterol-dependent cytolysins have been some of the
most promising (53-56). Structural homologs of human perforin, which is involved
in delivery of granzyme B (57), these cytolysins have evolved in bacteria as a tool for
escape from the phagosomes of macrophages (58) and have now been harnessed to
facilitate intracellular delivery of various biotherapeutics. In some cases they have
been directly attached to a therapeutically active molecule (59) or incorporated into
a combined liposomal formulation (37, 54). We've taken an entirely different
approach to using these membrane active proteins for targeted intracellular
delivery.
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Binding Internalization
SpH Trafficking
- Sorting
Degradation 0
Lysosomne Escape
Figure 1.3 - The intracellular delivery pathway. When a targeted biotherapeutic
binds to a cell surface it will, after some period of time, become internalized by one
of a variety of different mechanisms. Following internalization the endosomal
compartment is trafficked and may fuse with other sub-cellular compartments
while the conditions within begin to change, most important of which is a decrease
in pH. Most of these compartments will progress to lysosomes where enzymes will
degrade the contents, unless the biotherapeutic is released into the cytoplasm by
some other mechanism.
1.4 - Thesis overview
In this thesis, we describe a new intracellular biotherapeutic delivery system that
shows promise as a generalizable approach across antigen targets and active
therapeutic components. Beginning in Chapter 2, a new type of immunotoxin is
built that targets the plant toxin gelonin to cancer antigens with engineered scFvs
and fibronectin domains. We extend the standard characterization of
immunotoxins by quantitatively matching their internalization and cytotoxicity,
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which defines the precise number of molecules required to induce apoptosis. With
this new assay, we demonstrate conclusively that endosomal escape is the rate
limiting step of cytotoxicity for our gelonin immunotoxins. In Chapter 3 we
introduce our new intracellular delivery tool, targeted cytolysin, and demonstrate
its in vitro efficacy when administered in combination with gelonin immunotoxins.
Chapter 4 extends the system into in vivo experiments. And finally, in Chapter 5,
we briefly discuss the mathematical modeling techniques used to predict the
dynamics of the two-agent system in vivo and its therapeutic potential.
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Chapter 2 - Endosomal escape limitations of immunotoxins
2.1 -Abstract
Gelonin-based immunotoxins vary widely in their cytotoxic potency as a function of
antigen density, target cell internalization and trafficking kinetics, and conjugate
properties. We have synthesized novel gelonin immunotoxins using two different
binding scaffold types targeting two different tumor antigens. Constructs were
characterized using an antigen negative cell line, cell lines positive for each antigen,
and a cell line positive for both antigens. Immunotoxins exhibited Ka values
between 8-15 nM and showed 20-2000 fold enhanced cytotoxicity compared to
gelonin (IC5o 0.25-30 nM vs. 500 nM). We quantified internalization of gelonin
and gelonin-based immunotoxins and aligned the data with cytotoxicity
measurements made at equivalent concentration and exposures. When matched
internalization and cytotoxicity data were combined, a conserved internalized
cytotoxicity curve was generated, which was common across experimental
conditions. Considerable variations in antigen expression, trafficking kinetics,
extracellular immunotoxin concentration, and exposure time display a single
potency curve on the basis of internalized immunotoxin. Fifty-percent cytotoxicity
occurred when -5x10 6 toxin molecules were internalized regardless of the
mechanism of uptake. A threshold for apoptosis suggests that endosomal escape is a
common, highly inefficient rate-limiting step following internalization by any means
tested. Methods designed to enhance endosomal escape might be utilized to
improve the potency of gelonin based immunotoxins.
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2.2 - Introduction
Immunotoxins are a promising approach to the targeted delivery of highly potent,
cancer-specific cytotoxic agents. Immunotoxins are frequently composed of a
targeting moiety (derived from antibodies or other cell-binding proteins) either
chemically conjugated or genetically fused to highly cytotoxic plant or bacterial
protein toxins. Clinical success for immunotoxins has been mostly limited to
hematological malignancies due to transport limitations in solid tumors (1). Such
limitations have been extensively studied experimentally (2) and with several
computational models (3,4).
The potency of a particular immunotoxin is dependent on the ability to
deliver the toxin to the cytoplasm, which is commonly considered to be the rate
limiting step. For some native toxins such as ricin, intracellular delivery is
achieved through lectin binding followed by internalization and toxin release with
membrane fusion or retrograde trafficking (5). Immunotoxins attempt to recreate
this scenario by replacing the indiscriminate lectin binding with cancer-specific
antigen binding as a means of targeting and internalization (6). Subsequent
intracellular trafficking, release, and endosomal escape is often achieved using
existing toxin characteristics, translocation domains, protease cleavage sites,
disulfide bonds and/or signaling peptides (7-10). However, the inclusion of toxins
with domains facilitating cytoplasmic access can also lead to increased non-specific
toxicity in vivo (11,12).
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Gelonin is a plant toxin and classified as a type I ribosome inactivating
protein because it lacks any cell-binding or cytoplasmic delivery domains.
Recombinant gelonin (rGel) is a -30 kDa N-glycosidase with activity similar to ricin
A chain but exhibiting better stability and lower immunogenicity (13,14). The use
of rGel in tumor targeted cytotoxic agents has been well studied (15,16). Further,
rGel has been shown to be active without cleavage from the binding domain, and
without negative impact on the targeting agent's pharmacokinetics (17). The
necessity of internalization for activity of rGel immunotoxins and the antigen to
which it is directed have been previously demonstrated (18,19).
Carcinoembryonic antigen (CEA) is a 180 kDa membrane glycoprotein which
exhibits depolarized overexpression in numerous epithelial tumor types (20). The
utility of CEA as a tumor targeting tool for both therapy and imaging has been well-
established (21-23). Experiments in our laboratory have shown that CEA is
internalized with a half-life between 10 and 16 hours and thus represents a
potential target for immunotoxins (24). CEA has previously been used as a target
for the early development of immunotoxins (25-27). Epidermal growth factor
receptor (EGFR) has a strikingly faster internalization rate (-30 minutes).
However, many such internalized molecules return to the cell surface by recycling
(28). Like CEA, EGFR is a well established cancer-associated antigen. EGFR has
also been used as a target for designed immunotoxins (29,30). Previous studies
have suggested that antigens displaying similar expression levels but different
internalization rates can lead to profoundly different immunotoxin potencies (6).
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MFE-23 is an antibody single chain variable fragment (scFv) directed against
CEA. Originally identified by phage library selection, this scFv was later
humanized by resurfacing and engineered in yeast for greater stability, and
solubility (shMFE) as well as affinity (sm3E) (31-33). Both of these engineered
molecules are well-expressed in yeast and have Ka's of ~7nM and -30pM
respectively. The 10th human fibronectin type III domain (Fn3) has been designed
using various directed evolution approaches for specific affinity towards numerous
different targets (34-36). We describe engineered fibronectin fragments binding
EGFR and CEA (designated E246 and C743 respectively).
In this study we generated several novel immunotoxins targeting CEA and
EGFR, including the first published report of Fn3-based immunotoxins. Comparing
the different immunotoxin constructs, we investigated the mechanisms of cellular
intoxication including the cell-binding-dependent internalization of immunotoxins
and the subsequent loss of cell viability. Using a novel analysis of viability versus
net internalized antigen, a universal potency relationship was found which was
independent of the antigen, binding affinity/scaffold, internalization/recycling rate,
external immunotoxin concentration, and incubation time. This work may be useful
in understanding the mechanisms of immunotoxin-based cell killing and what
factors influence cellular intoxication. With a better understanding of these
mechanisms and factors we can engineer more effective agents as cell-targeted
therapeutics for cancer.
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2.3 - Methods
2.3.1 - Cell lines
The human fibrosarcoma cell line HT- 1080 was used throughout as an antigen
negative control. HT-1080 cells were transfected with a plasmid for CEA expression
and those cells, denoted HT-1080(CEA), were maintained under antibiotic selection
pressure from geneticin as previously described (24). The human epidermoid
carcinoma cell line A431 was used as an EGFR positive line and the human
colorectal carcinoma cell line HT-29 was used as a double positive cell line for both
CEA and EGFR.
2.3.2 - Construction of expression plasmids
The gene encoding the recombinant form of the gelonin toxin was codon-optimized
for E. coli expression and ordered from DNA 2.0 (Menlo Park, CA). The gene was
digested out of the synthetic vector using designed PstI and HindIII restriction sites
and cloned into the pMal-c2x expression vector encoding a maltose binding protein
(MBP) fusion product. Into this construct, Fn3 clones were inserted by
amplification of Fn3s out of their own expression vectors and using the purified
amplification products as primers for a QuikchangeTM insertion similar to the
protocol described by Geiser et a]. (37). The linker between the Fn3 and rGel was
modified to consist strictly of the amino acids encoded for by the necessary
restriction sites for binder cloning and a G4S linker sequence. In this setting,
various Fn3 and scFv genes could be inserted by restriction digestion and cloning
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using NheI and BamHI. As an alternative vector for expression we cloned the
immunotoxin construct by EcoRI and HindIII digestion into pET32a (Novagen)
expressing the product as a TrxA fusion. We further modified this vector by
mutating the protease site designed to remove the fusion tag from enterokinase to
tobacco etch virus.
2.3.3 - Protein expression and purification
The pMal-c2x vector containing the rGel gene was transformed into Origami 2
(DE3) (Novagen, San Diego, CA) and grown on LB agar plates containing ampicillin
and tetracycline. Colonies were picked from the plate and grown overnight at 37 *C
in 5 mL aliquots of selective media, which were then used to seed 1 L of antibiotic
free rich LB media and allowed to grow to logarithmic phase. Once the culture
reached an OD6oo between 0.5 and 1.0, 5 mL 0.1 M IPTG was added and the
induction was allowed to continue at 37 *C for 4hrs. Following induction cultures
were centrifuged at 15,000 xg for 12 min and cell pellets frozen at -20 *C. Pellets
were resuspended in amylose column buffer containing Complete EDTA-free
protease inhibitor (Roche, Indianapolis, IN) and then sonicated on a Branson
Sonifier 450A at 50% duty cycle and power level 5 for three, one-minute intervals.
The resulting solution was centrifuge at 50,000 xg for 30 min to pellet cell debris
and the supernatant was applied to an amylose column as described by the
manufacturer (New England Biolabs, Ipswich, MA). Purified recombinant proteins
were concentrated and buffer exchanged into Factor Xa digestion buffer using
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Amicon columns with a 30 kDa MWCO then incubated overnight at room
temperature with 5 pL Factor Xa (New England Biolabs). rGel (Appendix reference
- A.1) was isolated from the removed MBP and Factor Xa by ion-exchange
chromatography with a HiTrap Q column (GE Healthcare, Piscataway, NJ).
For production of immunotoxins, the Rosettagami 2 (DE3) bacterial host cell
line was used and chloramphenicol was added to plates and overnight growth media
as a selection agent. For Fn3-rGel immunotoxins, all other purification steps were
the same as for rGel expression. In the case of scFv immunotoxins the TrxA fusion
construct was used to facilitate more efficient formation of stabilizing disulfide
bonds. In this case, induction was carried out in standard LB media using 10 mL
0.1 M IPTG at 20 *C for 6 hrs. Purification of TrxA-scFv-rGel was achieved using
IMAC with TALON resin (Clontech, Mountain View, CA). The TrxA tag was
removed by digestion with TEV protease and the scFv-rGel was isolated from TrxA
and TEV by size-exclusion chromatography on Superdex 200 and 75 10/300 columns
connected in series.
Yields for rGel were approximately -3 mg/L after all purification steps. We
synthesized two Fn3 immunotoxins, one targeting CEA (C7rGel - A.2) and one
targeting EGFR (E4rGel - A.3), based on the affinity matured parent Fn3s C743
and E246. Yields for C7rGel and E4rGel respectively were -2.2 and -3 mg/L. We
synthesized two scFv immunotoxins, both targeting CEA, 3ErGel (A.4) and FErGel
(A.5), based on disulfide stabilized versions of the affinity matured scFv's sm3E and
shMFE (33). Yields for 3ErGel and FErGel respectively were -125 and -750 pg/L.
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Relative yields of each of the different immunotoxins and analysis by
polyacrylamide gel electrophoresis suggests that the primary reason for differences
in yields may be the proper folding and solubility for each immunotoxin. The
disulfide-stabilized scFv's appeared to disrupt folding, and thus soluble expression
yields, to a greater degree than Fn3s (although some of this difference may be due
to alternative fusion partners TrxA versus MBP). Similarly, the 3E scFv
destabilizes to a greater extent than the FE scFv in the context of the immunotoxin.
2.3.4 - Antigen binding affinity titration
Immunotoxins were biotinylated using amine reactive EZ-Link Sulfo-NHS-LC-
biotin (Pierce, Rockford, IL). Antigen positive cell lines HT-1080(CEA) and A431
were lifted from culture plates with trypsin and resuspended in 4% formalin for 30
min before being washed and stored in phosphate buffered saline with 1% (w/v)
bovine serum albumin (PBSA). Fixed cells were incubated with varying
concentrations of biotinylated immunotoxins overnight at 37 *C, washed once and
resuspended in 250 pL of PBSA with 1 pL goat anti-biotic FITC (Sigma, St. Louis,
MO) for 1 hr at 4 *C. Cells were washed once again and resuspended in 150 JIL
PBSA before being analyzed for fluorescence on an Accuri C6 flow cytometer. For
each titrating concentration, the median fluorescent intensity was determined and
data sets for each immunotoxin were fitted to a standard binding isotherm using
least-squares regression.
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Early attempts to titrate directly-labeled immunotoxins on fixed cells
resulted in a high non-specific background signal. Alternative approaches to
titration were attempted before we eventually arrived at the secondary detection
method described above. Titrations of all immunotoxins were performed on either
fixed HT-1080(CEA) cells or A-431 cells. Titration of the scFv immunotoxins
3ErGel and FErGel resulted in fitted Ka's of 8 nM and 15 nM respectively, which
were somewhat higher than the titrated affinity of their parental sm3E and shMFE
scFv's (Kd's ~ 30 pM and 9 nM, respectively, data not shown). We fitted the
titration data for Fn3 immunotoxins C7rGel and E4rGel and found Ka values of 10
nM and 13 nM respectively. These Ka's were also slightly higher than those found
for the parent Fn3s, 2 nM for C743 and 3 nM for E246. Differences in overall signal
were attributed to differences in the degree of biotinylation of immunotoxins.
Biotinylated rGel showed no significant signal when titrated over the same range of
concentrations.
2.3.5 - Cytotoxicity assays
Log-phase tumor cells were removed by trypsinization, counted, and seeded on 96-
well plates at 2,500 cells per well. Cells were allowed to adhere overnight after
which fresh growth media containing varying concentrations of rGel or
immunotoxin was added to triplicate wells. Toxins were incubated with the cells for
72 h before the toxin containing media was removed and replaced with media
containing the WST I reagent (Roche). The red/ox solution was allowed to develop
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for 1-3 h under normal culture conditions after which plates were measured for
absorbance at 450 nm. Untreated cells and cells lysed with a 1% Triton-X100
solution were used as positive and negative controls respectively. Measurements
were compared to baseline and normalized to control treatments, triplicates
averaged, and standard errors calculated. Time dependent cytotoxicity data were
obtained by treating cells as described, removing toxin containing media, washing
once with PBS, then replacing with fresh media for wells at each time point then
following identical assay procedures after 72 h. rGel cytotoxicity measurements
were made on concentrations between 1x10-9 and 3x10-6 M and times between 1 and
72 h. High antigen expressing cells were incubated with 10 nM either scFv
immunotoxin or 30 nM either Fn3 immunotoxin, while the low antigen expressing
line was incubated with 30 nM immunotoxin, with all incubations lasting between
12 and 72 h.
2.3.6 - Quantitative internalization
Cell lines were incubated with immunotoxins directly labeled with AlexaFluor 488.
At various times, cells were washed with PBS and incubated for 30 min with the
quenching rabbit anti-AlexaFluor 488 (Invitrogen, Carlsbad, CA). Cells were then
scraped from the wells, washed again with PBS, and analyzed for internal
fluorescent signal. Quantum Simply Cellular anti-Mouse IgG beads (Bangs
Laboratories, Fishers, IN) with different quantified binding capacities were
incubated with AlexaFluor 488 labeled mouse IgG for 30 min, washed with PBS,
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then measured for fluorescence. The number of fluorescent molecules per protein
on both immunotoxins and mouse IgG was determined using absorbance
measurements at 280 and 494 nm. Bead fluorescence measurements were used to
generate a standard curve for fluorescence signal per fluorescent molecule.
Immunotoxin internalization data were quantified by mapping fluorescence signal
to the bead fit converting signal to fluorescent molecules and then translated into
immunotoxin molecules using the labeling ratio.
2.3.7 - Internalized cytotoxicity
Data obtained in time dependent cytotoxicity experiments were combined with
those from quantitative internalization experiments and plotted to suggest the
former as the dependent variable and the latter as the independent variable.
Accumulated results were fitted using non-linear least squares regression of an
exposure-response curve with variable slopes using MATLAB (The MathWorks,
Natick, MA). From this fitting, half-maximum and near-full response metrics were
calculated and reported.
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2.4 - Results
2.4.1 - Novel gelonin -based immunotoxins
Four new immunotoxins were constructed which target CEA or EGFR. Three
different immunotoxins targeting CEA were constructed, using antibody scFv
fragments (3ErGel and FErGel), or a newly selected fibronectin scaffold-based
binding domain with specificity for CEA (C7rGel). The 3ErGel incorporates a high
affinity anti-CEA scFv sm3E described previously (33), while the FErGel
incorporates a lower-affinity precursor scFv, shMFE. As separate scFv molecules,
the affinities of these two binding modules are 30 pM (sm3E) and 9 nM (shMFE).
Using a yeast-displayed library of fibronectin scaffold proteins with randomized
loops, a new binding module targeting CEA was isolated (C743), with a Ka of 2 nM,
and another module that binds EGFR (E246) was isolated with a Ka of 3 nM. Each
of these four binding modules were expressed as N-terminal fusions to recombinant
gelonin, and binding of the resultant immunotoxin constructs was assessed with
tumor cell lines (Figure 2.1).
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Figure 2.1 - Immunotoxin affinity. Antigen affinity of binding fragments is
retained in their respective immunotoxin constructs. Four immunotoxins targeted
towards either CEA or EGFR via either scFv or Fn3 domain. The 3E and FE scFv
clones targeting CEA, the C7 fibronectin clone targeting CEA, and the E4
fibronectin clone targeting EGFR were each fused to rGel and titrated for binding
affinity on HT-1080(CEA) or A431 for CEA or EGFR respectively. Binding on fixed
cells was detected with goat anti-biotin FITC by flow cytometry. Data was fitted
using least-squares regression with a binding isotherm giving Ka's of 8nM for
3ErGel, 15nM for FErGel, 10nM for C7rGel, and 13nM for E4rGel.
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2.4.2 - Cytotoxicity ofrGel and immunotoxins
Results of concentration dependent cytotoxicity (Figure 2.2) suggest that
immunotoxin potency varies over two orders of magnitude, and is determined by a
complex combination of antigen density, binding affinity, binding scaffold, and
antigen internalization/recycling rate. On all cell lines tested gelonin shows IC 50
values around 500nM (Figure 2.2A). We find that all immunotoxins have an IC50 of
approximately 1 pM on the antigen negative HT-1080 cell line (Figure 2.2B). When
incubated with the double positive, low antigen expressing HT-29 cell line, all of the
immunotoxins again display IC5o values greater than or equal to 1 pM (Figure
2.2C). The exposure response curves on high antigen-expressing cell lines (Figure
2.2D) are consistent with previous results that apparent immunotoxin potency
varies widely when expressed solely as a function of extracellular concentration of
the agent and that each of the immunotoxins displayed a different IC 5o against
either HT-1080(CEA) or A431 (3ErGel = 250 pM, FErGel = 1.5 nM, C7rGel = 8 nM,
E4rGel = 30 nM).
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Figure 2.2 - Immunotoxin cytotoxicity. scFv and Fn3 immunotoxins show enhanced
cytotoxicity specific for antigen positive cells. (A) The IC5o of soluble rGel was
-500nM on all four cell lines used in the study. (B) Antigen negative cells (HT-1080)
were treated with the four different immunotoxins which displayed roughly
equivalent potency to soluble toxin. (C) Immunotoxins tested for cytotoxicity on the
double positive, low-antigen density HT-29 cell line. Surprisingly, none of the
immunotoxins show enhanced cytotoxicity compared to the IC5o of rGel. (D) On high
antigen expressing cells (HT-1080(CEA) and A431) greater potency is observed.
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2.4.3 - rGel time dependent internalization and cytotoxicity
rGel was incubated with HT-1080 cells for various lengths of time up to 72 h and
assessed for both internalization and cytotoxicity as described above, after which
data were combined to determine the internalized cytotoxicity profile (Figure 2.3).
Time dependent quantitative internalization results (Figure 2.3A) indicate that for
very low concentrations and very short times a minimum signal of roughly 1x10 4
molecules can be detected, likely due to autofluorescence from the cells above the
baseline bead autofluorescence. As treatment concentrations and incubation times
are increased the number of rGel internalized increases, peaking at nearly 1x10 7
molecules at 3 pM for more than 24 h. Time dependent cytotoxicity results (Figure
2.3B) show a similarly consistent theme in which low concentration, short time
treatments consistently result in viabilities between 80 and 100%. At the highest
concentrations and longest times, viability drops as low as 10%, while 50% viability
is achieved either by 3 pM concentration treatment for 12 h or by lower
concentration treatments for somewhat longer durations. By combining time
dependent quantitative internalization and cytotoxicity data to remove time as a
variable, an internalized cytotoxicity profile is obtained (Figure 2.3C). For the HT-
1080 cells treated with rGel, we found a wide variation in uptake and viability as a
function of concentration and time (Figures 2.3A & B). This data collapsed to a
fairly tight relationship between viability and the number of internalized gelonin
molecules and we noted a steep reduction in viability at approximately 5x10 6
internalized molecules (Figure 2.3C).
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Figure 1.3 - rGe] molecular cytotoxicity. Correlated internalization and cytotoxicity
measurements indicate a precise number of rGel molecules must be internalized by
a single cell before cytotoxicity is observed. (A) Time and concentration dependence
of rGel internalization by HT-1080 using the described quantitative internalization
flow cytometry assay. (B) Concentration and exposure matched cytotoxicity was
measured using the WST assay. (C) Data from A and B were combined and plotted
to show the dependence of cytotoxicity on the number of internal gelonin resulting
in the determination of the TN5 o near 5x10 6 .
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2.4.4 - Immunotoxin time dependent internalization and cytotoxicity
High antigen-expressing HT-1080(CEA) and A-431 cell lines as well as the low
antigen-expressing, double positive HT-29 cell line were incubated with
immunotoxins targeting the appropriate antigens for various times at
concentrations selected to show a wide change in viability over the range in time.
We assessed cells for immunotoxin internalization as well as viability following
incubations as described above and the data from the two measurements were
combined to determine the internalized cytotoxicity of the immunotoxins (Figure
2.4). Wide variation in uptake and viability with the different cell lines and
immunotoxins was observed (Figures 2.4A & B). However, the combined data for
internalized cytotoxicity surprisingly produced a curve consistent with that for
pinocytosed rGel, with a sharp reduction in viability once cells internalized more
than 5x10 6 molecules (Figure 2.4C).
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Figure 2.4 - Immunotoxin molecular cytotoxicity. Rate-limiting endosomal escape
in scFv and Fn3. (A) The internalization of immunotoxins by antigen positive cells
was measured by quantitative internalization flow cytometry at varying times and
concentrations. All HT-29 treatments and C7rGel/E4rGel treatments on HT-
1080(CEA) and A431 were made at 30nM while 3ErGel and FErGel treatments on
HT-1080(CEA) were made at 10nM. Antigen-dependent internalization is reported
by subtracting signal from cells blocked with unlabeled competitor. (B)
Concentration and exposure matched cytotoxicity from the WST assay. (C) Data
from A and B were combined and plotted to show the dependence of cytotoxicity on
the number of internal immunotoxins resulting in a TN5 o of -3x106 for all species.
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2.4.5 - Cumulative internalized cytotoxicity
Data collected from multiple experiments using each of the described cell lines with
various concentrations and exposures of rGel or one of the immunotoxins were
matched for internalized toxin levels and cytotoxicity as described and combined
into one cumulative internalized cytotoxicity plot (Figure 2.5). The entire data set
was accounted for irrespective of experimental conditions and used to fit an
exposure-response curve with variable slopes of the form:
100
[1+(x/TN50 )slope]
where both TN5 o and slope are fitted parameters. Fitting the exposure-response
curve parameters resulted in a TN5o = 4.68x10 6 and a slope = 1.86. The TN5o fit
describes the number of internalized immunotoxins necessary to induce a 50% loss
of viability. Additionally, in situations such as this where we observe a strong step-
function response characterized by a large slope parameter, it is useful to consider
values associated with a more complete response. Here we consider the TN9 o as
calculated from the fit using the equation:
TN90 = TN50  00-90 e(100 -90)
The resulting TN9 o indicates that 1.53x10 7 molecules of toxin must be internalized
on average for 90% of the population to undergo apoptosis. In other words, when
the average population uptake reaches the TN9o, only one-tenth of the population
has failed to achieve the -5x10 6 molecule limit for toxicity. The plotted cumulative
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internalized cytotoxicity data are each a median value of a Gaussian distribution of
cells internalizing different numbers of toxin molecules as measured by flow
cytometry (Figure 1.5). Thus, for each data point, half of the cells in the treatment
population internalized more than the recorded number and half took up less. So at
the TN5 o, 50% of the cells died, and 50% internalized at least -5x10 6 molecules
indicating that this is indeed the average threshold for loss of viability in a single
cell.
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Figure 2.5 - Cumulative molecular cytotoxicity. Aggregated data from experiments
using different binding scaffolds, antigen targets, affinities, and cell lines all
converge to the same TN5 o curve. Accumulated internalized cytotoxicity data for
rGel on all cell lines and immunotoxins on antigen high and antigen low cells. The
cumulative data set was fit using an exposure response curve with variable slopes
giving a TN5 o of 4.7x10 6 and with an exponential decay curve giving a k value of
1.6x10 7 which can be converted to a half-decay or TN5 o of 4.3x10 6.
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2.5 - Discussion
The importance of internalization for the efficacy of immunotoxins is well
appreciated (6,18,39,40). However, these studies clearly indicate that a type I toxin
such as gelonin exhibits quantitatively the same low intracellular potency
regardless of the particular pathway which drives internalization. Delivery of the
cytotoxic domain of an immunotoxin to the cytoplasm of a cell is dependent upon a
series of steps, each with a varying degree of efficiency depending on the cell type,
antigen density, binding affinity, internalization/recycling, and sub-cellular
trafficking or endosomal escape. Due to the enzymatic potency of ribosome
inactivating proteins, only a few toxin molecules successfully delivered to the
cytoplasm (or ribosomal compartment) may be lethal to the cell (41). Quantitative
measurement of levels this low is exceedingly difficult and it is therefore difficult to
directly determine a rate of translocation or escape of molecules into the active
compartment. Alternatively, we chose to quantify the total intracellular level of
immunotoxins, and infer their cytoplasmic access by the resulting cytotoxicity.
Strikingly, there is an apparently near-universal requirement for approximately
5x10 6 gelonin molecules to be internalized in order to kill a tumor cell, regardless of
the route of vesicular internalization.
Buildup of such a significant number of toxins intracellularly, given the
efficiency of the enzyme once in the cytoplasm, suggests not only that binding and
internalization of immunotoxin is quite efficient, but also that endosomal escape is
the rate-limiting step in the process of intoxication. If endosomal escape were more
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efficient, cells would become intoxicated much faster and such high levels of
internalization would not be observed. Nevertheless, it should be acknowledged
that these data might also be explained by a rate limiting degradation of toxin
assuming retention of fluorescence.
Here we have synthesized a novel set of immunotoxins based on binding
domain fusions to the plant toxin gelonin. We have used ds-scFv's engineered for
affinity towards CEA as well as Fn3s engineered for affinity towards CEA and
EGFR. To our knowledge, this is the first published report of Fn3-targeted
immunotoxins. Studies describing rGel fusions with fibronectin fragments
targeting IGF1R were recently reported (AACR 2010). We examined the ability of
these binding scaffolds to retain affinity within the fusion construct and found that
while affinity is retained to a considerable degree, there was some loss of affinity
compared to the parent molecule likely attributable to partial misfolding and
instability in the fusion construct. This is consistent with work by others designing
direct fusion immunotoxins (42,43). We believe that this misfolding and instability
also influences the synthetic yields of each of the immunotoxins. Those constructs
showing the greatest loss of parent affinity also have the lowest yields. Despite
losses of relative affinity, all of the immunotoxins still bound their respective
antigens with low nanomolar affinities.
Development of the new class of Fn3-based immunotoxins is an attempt to
overcome two of the most substantial limitations to immunotoxin therapy.
Commonly, these therapies are limited by vascular toxicity and a failure to
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infiltrate the tumor mass. The smaller Fn3 scaffold (-10 kDa) should allow for
more rapid clearance from the vasculature thereby minimizing exposure, and
maximize the diffusion coefficient to optimize tumor penetration under fast
clearance conditions. It is well established that molecules smaller than the 60-70
kDa molecular weight cut-off for renal filtration are rapidly cleared (44). And while
this clearance itself limits total tumor targeting, our lab's mathematical models
suggest that the smaller molecular weight should lead to a more homogenous
immunotoxin distribution within the tumor (4). We plan to test whether these
hypotheses regarding the pharmacokinetics of Fn3 immunotoxins are validated by
in vivo experiments. This work and others has shown that Fn3 scaffold is capable
of mediating antigen specific binding at affinities on par with scFv or IgG at a
fraction of the molecular weight.
Antigen binding by scFv or Fn3 domains was sufficient to enhance gelonin
potency towards antigen positive cells between 20 and 2000 fold depending on
scaffold, affinity, antigen internalization/recycling and antigen density.
Immunotoxins showed no increase in cytotoxicity compared to rGel on antigen
negative cells and cells expressing low levels of antigens. These results support
previous examples using scFv fusions to enhance toxin potency (17) and validate
Fn3 as a new targeting agent with improved stability and expression, due in part to
an absence of disulfide bonds, for immunotoxin design. Fn3 based immunotoxins
have the added advantage of being smaller in size allowing them to potentially
better penetrate tumors due to improved capillary permeability and diffusion.
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In an attempt to better understand the subcellular barrier to cytotoxicity, we
measured the molecular internalization of rGel in HT-1080 cells. Using identical
treatments, we determined the cytotoxicity resulting from the measured
internalization. As toxin concentration and incubation time were increased, the
number of molecules internalized per cell increased and the population viability
decreased. When viability was plotted as a function of internalized molecules a
strong non-linear relationship was found, independent of incubation time and
concentration. We hypothesize that the number of internalized molecules required
to induce a 50% loss in viability, TN5 o, is determined primarily by the rate of
endosomal escape and cytoplasmic access. Conversely, one might have expected
that antigen binding might actually deter the rate of intoxication following
internalization, based on the success of methods enhancing cytotoxicity by
incorporating release elements between binding and toxin domains (45,46).
However, the overlap in the internalized immunotoxin cytotoxicity curve for
antigen-bound and internalized immunotoxin vs. pinocytosed free gelonin indicates
that release of immunotoxins from antigen binding plays a negligible role in
intoxication.
The described technique for determining TN5o does not address the precise
fate of the immunotoxins following endocytosis. Murphy and coworkers have
modeled the intoxication process for diphtheria and gelonin immunotoxins in great
subcellular detail and fitted model parameters to protein synthesis inhibition data,
finding that the translocation rate constant for gelonin, approximately 5x10-8 min-1
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is several orders of magnitude slower than that of diphtheria alternatives and
independent of the targeting moiety (16,47,48). In this work, they conclude that for
every 106 internalized gelonin immunotoxin molecules, only one reaches the
cytoplasm (16) - a result in striking quantitative agreement with the measured TN5o
of -5 x 106 in the present work. It should be noted that those experiments focused
on protein synthesis inhibition rather than a direct measure of cell viability.
Utilizing the reported technique, it is likely that immunotoxins incorporating toxins
with dedicated translocation domains will show lower TN5o values depending on the
efficiency of their endosomal escape machinery. However, such added functionality
is likely to contribute directly to off-target toxicity in vivo.
The subcellular barrier to delivery is common to all therapeutic
macromolecules requiring cytoplasmic access. Many groups interested in the
delivery of siRNA have investigated various tools for overcoming this barrier
including endosome disrupting polymers (49). Our measurements of the number of
toxin molecules required to achieve a single translocation event should be a useful
assay for investigating the potential of these tools to enhance intracellular delivery
in a quantitative way.
In the future, assessment of novel immunotoxin constructs should be more
thorough when potency is evaluated both by the traditional extracellular
concentration response metric and the internalized cytotoxicity measurement
presented here. Having designed novel, potent immunotoxins, engineering efforts
should now be properly directed either towards designing molecules with improved
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intracellular uptake (e.g. tumor delivery/penetration, antigen density, binding
affinity, internalization kinetics, and tumor retention), or which have improvements
in the efficiency of intracellular trafficking to the biologically active compartment.
These results should have a significant impact on the rational design of
immunotoxins and their combination therapies.
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Chapter 3 - An in trans targeted intracellular delivery system
3.1 - Abstract
Molecular targeting technology has led to the advent of macromolecular
therapeutics capable of tissue specific intervention. But the use of this technology
in the field of intracellular drug delivery has been limited and consequently there
exists a need for a broadly applicable targeted intracellular delivery system. We've
designed an independently targeted drug delivery system based on engineered
fibronectin domains fused to bacterial cytolysins. The designed fusion proteins had
binding affinities in the single digit nanomolar range to their respective antigen
targets and showed antigen-dependent cytotoxicity correlated with hemolytic
activity. Delivery capability of the system was validated using gelonin
immunotoxins whose exquisite cytoplasmic activities make them ideal candidates
for exhibiting enhancement of intracellular delivery. in vitro experiments
demonstrated the ability of these fusion proteins to synergize in antigen-specific
cytotoxicity, reducing the number of internalized toxins required to induce apoptosis
from -5x10 6 to < 104. These results convey both the potential of this particular
application in cancer therapy and of our general approach to intracellular delivery
of therapeutic macromolecules.
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3.2 - Introduction
For decades researchers have pursued a means by which to deliver therapeutic
macromolecules such as DNA, RNA, and proteins to the cytoplasm of cells in order
to affect intracellular targets. The in vivo efficacy of any macromolecular
therapeutic is fraught with numerous challenges, not the least of which is
endosomal escape (1). Within the fields of gene therapy and RNA interference, the
challenge of intracellular delivery is appreciated, and the value of accomplishing
that delivery in a targeted manner is well understood (2, 3). The same is true for
protein drugs(4, 5); delivery of protein antigens to antigen presenting cells for
display is also enhanced by various mechanisms of endosomal disruption (6, 7).
Despite measured successes, there remains a critical unmet need for an effective,
targeted intracellular delivery approach.
Immunotoxins are a class of proteins whose intracellular delivery is of
particular importance. Early developers of immunotoxins diverged in their use of
various types of toxins, generally working with either type I or type II toxins (8).
Researchers working with type II toxins, such as diphtheria toxin, ricin, or
pseudomonas exotoxin, never concerned themselves with intracellular delivery
because these toxins incorporate their own evolved translocation domains or other
components that facilitate endosomal escape (9-11). Meanwhile, those working with
type I toxins investigated various small molecule and protein based methods for
enhancing translocation(12-17). In some cases, potent intracellular delivery agents
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have been identified, but specificity remained elusive and toxicity was often a
confounding factor.
The bacterium Listeria Monocytogenes produces the unique protein
listeriolysin 0 (LLO) as a tool for endosomal escape from phagosomes in
macrophages. What makes LLO unique is that, unlike other cytolysins, it is only
active within the lysosomal compartment. Once the bacterium and protein are
release into the cytoplasm, LLO is inactivated through a variety of mechanisms
(18), the most important of which is due to its pH sensitivity (19). LLO and other
cytolysins have been used previously as tools for the delivery of biotherapeutics
including DNA and proteins (20-23). LLO has also been used as the cytotoxic
component of an immunotoxin (24). Homologs in the cholesterol-dependent cytolysin
(CDC) family (25) include perfringolysin 0 (PFO) and streptolysin 0. Because of
their mechanism of action and the established difficulty in the delivery of our
immunotoxins, we hypothesized that targeted type I immunotoxins and targeted
CDCs might synergize through enhanced intracellular delivery.
We have previously designed a set of immunotoxins based on engineered
binding affinity variants of the 10th type III human fibronectin (Fn3) domain
targeting either the carcinoembryonic antigen (CEA) or the epidermal growth factor
receptor (EGFR) fused to recombinant, plant type I ribosome inactivating protein
gelonin (rGel) (26). These immunotoxins showed enhanced, targeted cytotoxicity
towards highly-expressing antigen positive cells. However, they were impotent
against lower-expressing cell lines leading us to investigate and quantify the
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endosomal escape efficiency of the immunotoxins. Other work in this field indicates
that only -5 immunotoxin molecules are required to reach the cytoplasm in order to
induce apoptosis, yet our findings suggested -5 million immunotoxin had to be
internalized to reach this apoptotic threshold. This result encouraged us design
tools capable of inducing targeted endosomal disruption.
Specifically, we sought to develop a system for delivering a therapeutic
macromolecule to the cytoplasm of a cell in a targeted manner. Using the same
engineered Fn3s as our gelonin immunotoxins, we created targeted fusion proteins
with LLO and PFO. The fusion proteins were expressed recombinantly in E. coli,
conserved antigen-specific binding, and showed some antigen-dependent
cytotoxicity. Membrane disruptive hemolysis, a characteristic of CDCs, was also
conserved. When combined in cell treatments with gelonin immunotoxins these
fusions exhibited potentiating activity, decreasing the IC5o values of immunotoxins
by several orders of magnitude. Potentiation was observed when the two agents
were targeted to the same antigen competitively, when targeted to different
antigens known to colocalize, and even when targeted to cells expressing low levels
of antigens. We went on to test the ability of fusions to potentiate immunotoxin
activity when the two agents were applied to cells at different times and to quantify
the reduction in the intracellular barrier to delivery, which was consistent with the
improvement in cytotoxicity suggesting that the observed synergistic effects are the
result of membrane destabilization or pore-formation by the cytolysins leading to
release of immunotoxin.
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This in trans approach to intracellular delivery is a departure from
traditional intracellular delivery methods in which the membrane disruptive agent
and the therapeutic payload are directly connected. Two different agents targeting
the same cell can become colocalized within the same endosomal compartment
where the potentiating agent facilitates the release of the therapeutic payload
(Figure 3.1).
Antigen 1
A t Antigen 2
Antigen 1 Targeted
Biotherapeutic
Lysosome Antigen 2 Targeted
Endosomes Lysin
Cytoplasm I
Destabilized
Endosome
B
Figure 3.1 - Targeted in trans intracellular delivery. The central concept of this
work is that separately targeted membrane disrupting functionality can be
delivered to tumor cells via Fn3-cytolysin fusions. Simultaneous targeted delivery
of such a potentiator to tumor cells that internalize by endocytosis an independently
targeted biotherapeutic will potentiate the immunotoxin by improving its leakage to
the cytoplasm, its site of action. By separating the membrane-crossing and toxic
moieties, we are able to dramatically improve specificity and potency. The
traditional fate of intracellularly active biotherapeutics (A) leads to degradation in
the lysosome, but upon compartmental colocalization of biotherapeutic and
potentiator (B), the lysins' membrane disruptive characteristics release the
biotherapeutic into the cytoplasm
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3.3 - Methods
3.3.1 - Cell lines
To obtain an appropriate cross section of the different antigens targeted, we utilized
four different established human cancer cell lines. HT- 1080 is a human
fibrosarcoma cell line negative for CEA. HT-1080(CEA) is a transfected variant of
HT-1080 which expresses CEA at high levels (~2x106 copies/cell) on its surface
through the pIRES-CEA plasmid, which is maintained under selective pressure
from geneticin at 250 gg/mL. Both HT-1080 and HT-1080(CEA) also express ~1x10 5
copies of EGFR. A431 is a human epidermoid carcinoma cell line that highly
expresses EGFR (~3x106 copies/cell) but not CEA. HT-29 is a human colorectal
carcinoma cell line that expresses lower levels of both CEA and EGFR (~1x105
copies/cell).
3.3.2 - Colocalization microscopy
1 x 105 HT-29 cells were cultured on MatTek dishes with 0.13mm coverslip bottoms
in 200 gL of growth media to which Alexa584-sm3E anti-CEA single-chain antibody
variable fragment (7 pM, DOL 1.85) and Alexa488-225 anti-EGFR antibody (5uM,
DOL 6) were added with final concentrations of 11.7 nM and 33 nM, respectively.
The cells were maintained in this solution under standard culture conditions (37 *C,
5% CO 2) for 15 hours, after which the cells were washed three times with PBS and
returned to growth media for 30 minutes before imaging. Cells were serum starved
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prior to treatment. Images were taken under 60x magnification on an inverted
Olympus X71 Deltavision deconvolution microscope.
3.3.3 - Construction of expression plasmids
Genes encoding LLO and PFO proteins were codon-optimized for expression in E.
coli and ordered from GenScript (Piscataway, NJ). Genes were amplified by PCR
using primers designed with 3' complimentarity to either end. After being purified
from an agarose gel, the gene product was inserted into the same fusion construct
used previously for our immunotoxin synthesis by the method of Geiser et aL. (26,
27). The resulting plasmid encoded an open reading frame including, from N-
terminus to C-terminus: maltose binding protein, Nio linker, Factor Xa protease
site, an engineered 10th Type III fibronectin domain, a G 4S linker, and LLO or PFO.
Additionally, our PFO gene was truncated to remove an unnecessary secretory
sequence and its construct modified to incorporated a tobacco-etch virus protease
site N-terminal to the constant Factor Xa site.
3.3.4 - Protein expression and purification
Immunotoxins were synthesized as described previously (26) and Fn3-LLO/PFO
(A.6, A.7, A.8, and A.9) production was conducted in a similar manner. Briefly, the
appropriate plasmids were transformed into Rosetta (DE3) E. coli (Novagen, San
Diego, CA) and grown on LB agar plates supplemented with ampicillin and
chloramphenicol. Colonies were isolated from the plate and used to inoculate 15 mL
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of selective media which incubated overnight at 37 *C. Cultures were used to
inoculate 1 L of antibiotic free LB media and grown to an OD60 0 ~0.5 at which point
5 mL of 0.1M IPTG was added and the cultures moved to incubate at 30 *C for 6
hours. Following induction, cultures were centrifuged at 15,000 x g for 12 minutes,
the supernatant removed, and the cell pellets frozen at -20 *C. Pellets were
resuspended in 25mL amylose column buffer containing Complete EDTA-free
protease inhibitor (Roche, Indianapolis, IN) and then sonicated on a Branson
Sonifier 450A (Branson Ultrasonics, Danbury, CT) at 50% duty cycle and power
level 6 for three, one-minute intervals. The resulting solution was centrifuge at
50,000 x g for 30 minutes to pellet cell debris and the supernatant was applied to an
amylose column as described by the manufacturer (New England Biolabs, Ipswich,
MA). Purified recombinant proteins were concentrated and buffer exchanged into
Factor Xa/TEV protease digestion buffer using Amicon columns with a 100 kDa
MWCO then incubated overnight at 4*C with 5 iL Factor Xa/TEV protease (New
England Biolabs/Invitrogen). Fn3-cytolysin was isolated from the cleaved MBP and
Factor Xa/TEV protease by ion-exchange chromatography with a HiTrap Q column
(GE Healthcare, Piscataway, NJ).
3.3.5 - Antigen binding affinity titration
Fn3-LLO was biotinylated using amine reactive EZ-Link Sulfo-NHS-LC-biotin
(Pierce, Rockford, IL). Antigen positive cell lines HT-1080(CEA) and A431 were
lifted from culture plates with trypsin and resuspended in 4% formalin for 30
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minutes before being washed and stored in phosphate buffered saline with 1% (w/v)
bovine serum albumin (PBSA). Fixed cells were incubated with varying
concentrations of biotinylated fusion protein overnight at 37 *C, washed once and
resuspended in 250 pL of PBSA with 1 pL streptavidin-phycoerythrin conjugate
(Sigma, St. Louis, MO) for 1 hour at 4 *C. Cells were washed once again and
resuspended in 150 iL PBSA before being analyzed for fluorescence on an Accuri C6
Flow Cytometer (Accuri Cytometers, Ann Arbor, MI). For each titrating
concentration, the median fluorescent intensity was determined and data sets for
each immunotoxin were fitted to a standard binding isotherm using least-squares
regression with the Excel (Microsoft Corp., Redmond, WA) solver tool.
To titrate Fn3-PFO fusions, CEA (R&D Systems, Minneapolis, MN) was
biotinylated using amine reactive EZ-Link Sulfo-NHS-LC-biotin (Pierce).
Biotinylated CEA was loaded streptavidin coated magnetic beads (Invitrogen,
Carlsbad, CA), and incubated with varying concentrations of C7PFO for 6 hours at
4 *C. EGFR 404SG ectodomain was expressed on the surface of yeast(28), and
incubated with varying concentrations of E6PFO for 6 hours at 4 *C. Cells or beads
were washed once and resuspended in 50 iL of PBSA with 0.25 pL of rabbit anti-
His6 antibody (Abcam, Cambridge, MA) which was labeled with the Alexa 647
Microscale Protein Labeling Kit (Invitrogen) for 30 minutes at 4 *C. Cells or beads
were washed twice with 200 pL PBSA before being analyzed for fluorescence by flow
cytometry.
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3.3.6 - Hem olysis
Experiments were conducted to determine the degree to which Fn3-cytolysin would
disrupt red blood cell membranes using a method similar to that described by
Henry et aL. (29). Briefly, purified mouse red blood cells (Fitzgerald, Acton, MA)
were washed twice with PBSA at either pH 7.4 or pH 5. Cells were mixed with
fusion protein at varying concentrations in the same buffer to a final cell
concentration of -1x10 9 cells/ml. Cells and protein were incubated at 37 *C for 1
hour before treatments were centrifuged at 13,500 x g for 5 minutes. Supernatants
were transferred to 96-well plates and absorbance read at 540 nm. Results were
normalized to a PBS negative control and 1% Triton-X100 positive control.
3.3.7 - Cytotoxicity
Log-phase tumor cells were lifted by trypsinization, counted, and seeded on 96-well
plates at 2,500 cells per well. Cells were allowed to adhere overnight, after which
fresh growth media containing varying concentrations of Fn3-cytolysin and/or
immunotoxin was added to triplicate wells. Cells were incubated in treatment
media for 48 hours before being replaced with media containing the WST I reagent
(Roche). The red/ox solution was allowed to develop for 1 hour under normal
culture conditions after which plates were measured for absorbance at 450 nm.
Untreated cells and cells lysed with a 1% Triton-X100 solution were used as positive
and negative controls, respectively. Measurements were set to baseline on negative
control and normalized to positive control treatments, triplicates averaged, and
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standard deviations calculated. Delayed dose or time dependent cytotoxicity data
were obtained by treating cells as described for 12 hours with immunotoxin,
removing treatment containing media, washing once with PBS, then replacing with
fresh media or media containing the potentiating agent for wells at 0, 12, 24, or 48
hours from initial immunotoxin exposure, then following identical assay procedures
after 72 hours. In situations where one agent was titrated and the other was fixed
or where both agents' concentrations were fixed, the fixed concentration was
selected so as to be non-toxic in the absence of the other agent.
3.3.8 - Statistical analyses of synergy
To quantify the extent of synergy between gelonin immunotoxins and targeted
cytolysins in vitro we used designed cytotoxicity co-titrations to calculate
combination index (CI) and cumulative combination data to calculate synergy
assessment factor (SAF). The combination index metric was first used to determine
the synergistic effects of mutually exclusive and mutually non-exclusive enzyme
inhibitors by Chou and Talalay (30, 31). Synergy assessment factor is a more recent
treatment of synergistic effects which was inspired by combination index. It was
first put forth by Yan et al. as it pertained to synergy within signaling networks(32)
and is equivalent to the fractional product equation described by Webb(33). For CI
calculations we simultaneously titrated immunotoxins and used 0.9 fraction
affected as the analysis point.
[IT] [P] [IT] x [P]
IT90 P90 (IT, P) 90
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Alternatively, when using SAF we chose to calculate the metric for all titrations and
data points then averaged for cell line or immunotoxin/potentiator of interest.
SAF = FA(IT, P) - FA(IT) x FA(P)
3.3.9 - Quantitative internalization
Cell lines were incubated with immunotoxins directly labeled with AlexaFluor 488
and unlabeled Fn3-cytolysin. At various times, cells were washed with PBS and
incubated for 30 minutes with the quenching rabbit anti-AlexaFluor 488
(Invitrogen). Cells were then scraped from the wells, washed again with PBS, and
analyzed for internal fluorescent signal. Quantum Simply Cellular anti-Mouse IgG
beads (Bangs Laboratories, Fishers, IN) with different quantified binding capacities
were incubated with AlexaFluor 488 labeled mouse IgG for 30 minutes, washed
with PBS, then measured for fluorescence. The number of fluorescent molecules per
protein on both immunotoxins and mouse IgG was determined using absorbance
measurements at 280 and 494 nm. Bead fluorescence measurements were used to
generate a standard curve for fluorescence signal per fluorophore. Immunotoxin
internalization data were quantified by mapping fluorescence signal to the bead fit,
converting signal to fluorescent molecules and then translated into immunotoxin
molecules using the labeling ratio.
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3.3.10 - Internalized cytotoxicity
Data obtained in time dependent cytotoxicity experiments were combined with
those from quantitative internalization experiments and plotted to suggest the
former as the dependent variable and the latter as the independent variable as in
our previous work (Chapter 2). Accumulated results were fitted using non-linear
least squares regression of an exposure-response curve with variable slopes using
MATLAB (The MathWorks, Natick, MA). From this fitting, a mid-range response
metric was calculated and reported.
3.4 - Results
3.4.1 - EGFR and CEA intracellular colocaliza tion
HT-29 cells express approximately 1x10 5 copies each of both EGFR and CEA on
their surface. These cells were treated with fluorescently labeled anti-EGFR IgG
and anti-CEA scFv. Subsequent microscopy images showed that both antigens were
bound and internalized showing punctuate staining (Figure 3.2). Further, the
merging of the images from the two fluorescent channels indicates strong
colocalization. Colocalization was characterized using image analysis software and
found to have a positive Pearson's coefficient of correlation of 0.76.
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Merge
Figure 3.2 - Colocalization of intracellular EGFR and CEA. HT-29 cells that
express both EGFR and CEA show that agents targeted to these two receptors will
colocalize to a considerable extent to the same intracellular compartments, a
necessary condition for the success of the proposed potentiation strategy. An anti-
EGFR antibody was labeled with AlexaFluor-488 and an anti-CEA scFv was labeled
with AlexaFluor-594 before both were used to label HT-29 cells to observe
colocalization.
3.4.2 - Cytolysin fusion synthesis and in vitro characterization
Novel fusion proteins of the Fn3-LLO and Fn3-PFO types were designed with
targeting to EGFR and CEA. Fusions were derived from Fn3 clones E626 and
C743, which bind to EGFR and CEA with Kd's of 260 pM and 1.8 nM, respectively
and were engineered and assayed for antigen affinity as described by Pirie et aL.
(26). The fusions were expressed in E. coli at -100 pg/L for Fn3LLO and ~1.5 mg/L
for Fn3PFO. Non-linear regression fitting shows that the Kd's for the fusion
proteins are 5.0 nM for E6LLO, 4.1 nM for C7LLO, 4.1 nM for E6PFO and 4.1 nM
for C7PFO (Figure 3.3A).
Given our understanding of cytolysin activity and the work of Bergelt et a].
(24), we realized that it was important to assess the direct cytotoxicity of the Fn3-
cytolysins. The independent cytotoxicity of the fusions was tested by titration on a
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EGFR CEA
variety of antigen positive and antigen negative cell lines. Fitting the data with
concentration-response curves with variable slopes gave IC5o values that correlated
inversely with antigen expression level (Figure 3.3B). These data show that
targeted LLO and PFO fusions do indeed possess some inherent cytotoxicity and
that, much like gelonin fusions, their cytotoxicity is related to specific binding of cell
surface antigens.
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Figure 3.3 - Cytolysin fusion binding and cytotoxicity. (A) Biotinylated Fn3-LLO
fusions were titrated against fixed A431 or HT-1080(CEA) cells, while Fn3-PFO
fusions were titrated against antigen-coated beads or antigen-displaying yeast.
Fusions showed binding affinity Kd's in the low nM range, only slightly reduced
relative to the parent Fn3 affinity. (B) Fusions were added to growth media on cells
with varying antigen expression levels. For each cell type, Fn3-cytolysin
cytotoxicity correlated with antigen expression level.
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A common assay in the characterization of bacterial CDCs and other
membrane disruptive materials is the hemolysis assay. The ability of Fn3-cytolysin
fusions to disrupt red blood cells at either physiological or endosomal pH can be
representative of non-specific toxicity and activity respectively. We were
particularly interested in assessing hemolysis because of work suggesting very low
toxicity limits of LLO in vivo (19). At pH 7, the EC5o for membrane disruption by
E6LLO was ~500 nM, while at pH 5 it was -3 nM. For E6PFO the EC5o's were 25
pM and 4 pM respectively (Figure 3.4). This data is consistent with work by Jones
and Portnoy that queried LLO and PFO properties and found similar hemolytic
characteristics (34).
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Figure 3.4 - Cytolysin fusion hemolytic activity. Fn3-cytolysins were incubated
with mouse red blood cells at either physiological (7) or endosomal pH (5). Fusions
showed the expected pH dependent response at concentrations consistent with their
non-specific toxicity and potentiating activity.
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3.4.3 - Potentia ted immunotoxin cytotoxicity in vitro
In this study we've used two different immunotoxins E4rGel and C7rGel targeting
EGFR and CEA respectively that have been described previously (26). These
immunotoxins show independent IC5o's of approximately 30 nM and 5 nM
respectively on cell lines expressing high levels of antigen. However, on HT-29 cells
that express low levels of antigen, the immunotoxins appear no more potent than
untargeted toxin with IC5o's around 1 jiM. Remarkably, when we titrate the
immunotoxins in the presence of non-toxic levels of Fn3-cytolysin, the potency is
increased by several orders of magnitude. We find that on high antigen expressing
cells, the IC5o of E4rGel is decreased from 30 nM to -50 pM and that of C7rGel is
potentiated from about 1 nM to the single digit pM range (Figure 3.5). When both
agents are titrated at a fixed ratio, the independent titrations are non-toxic, while
the combination shows synergistic cytotoxicity. Perhaps most importantly, we were
able to show that otherwise ineffective immunotoxin can be activated to an
equivalent degree on HT-29 cells where the IC5o's shift from 1 PM to 1 nM (Figure
3.6A). This shift was consistent for both non-competitively co-targeted
immunotoxin and potentiator and for differentially targeted components.
To statistically support the observed synergy between gelonin and cytolysin
immunotoxins we employed two different metrics: combination index (CI) and
synergy assessment factor (SAF). Qualitatively, CI values are characterized as
antagonistic when > 1, additive when = 1, and synergistic when < 1. Alternatively,
SAF will = 0 when a combination is additive, > 0 when antagonistic, and < 0 when
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synergistic. We report here examples of Ch9 o values less than 1 and negative SAF
values indicative of the strong synergy (Figure 3.6B) we observed across all
cytolysin fusions when combined with gelonin immunotoxins on any cell line. The
strength of each synergy metric tended to show an inverse correlation with the
independent potency of the gelonin immunotoxin on the cell line in question.
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Figure 3.5 - Potentiation of gelonin immunotoxin cytotoxicity. (A) Potentiation of
anti-EGFR immunotoxin E4rGel using the non-competitive, co-targeted potentiator
E6LLO on A431 cells. (B) anti-CEA immunotoxin C7rGel potentiated by the
competitive potentiator C7LLO on HT-1080(CEA) cells. (C) Titrations of C7rGel and
E6PFO on HT-29 cells achieve only modest toxicity alone, but when titrated
together at the same concentrations, much greater toxicity is observed.
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Figure 3.6 - in vitro potentiation. Fn3-cytolysins were first tested in vitro to show
that the fundamental IC5o of Fn3-rGel's could be lowered. (A) HT-29 cells titrated
with immunotoxins targeting either EGFR or CEA experience only limited
cytotoxicity up to iM concentrations. But in the presence of non-toxic levels of
potentiator, these same immunotoxins have IC5o's around 1 nM. (B) For two EGFR
targeted potentiators, combination index (CI) and synergy assessment factor (SAF)
are calculated for their effect on HT-1080(CEA) and HT-29 in the presence of
C7rGel.
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3.4.4 - Internalized cytotoxicity with potentiated TNso
Previously we have shown that there is an intracellular barrier to immunotoxin
potency which requires that -5x1O 6 toxin molecules be internalized before a cell will
undergo apoptosis (26). Furthermore, it was established that this barrier was
common to all gelonin immunotoxins tested regardless of cell type, antigen targeted,
or binding affinity. We utilized the same techniques to characterize the
intracellular barrier in the presence of potentiator. The number of anti-CEA
immunotoxins internalized by HT-29 cells increased with proportionally with
treatment concentration and incubation time (Figure 3.7A). However, the number
is still significantly less than would be necessary to induce cytotoxicity without of
potentiator, yet loss of viability is observed in treatment cells (Figure 3.7B).
When we combine data from internalization and cytotoxicity measurements
we get internalized cytotoxicity curves that indicate TN5 o values less than 104
molecules, a several order of magnitude drop in the delivery barrier mediated by the
presence of potentiator (Figure 3.7C). In fact, we are unable to directly ascertain
the true TN5o in the presence of potentiator because the fluorescent signal from so
few molecules is indiscernible from autofluorescence of the cells. To give a sense of
the magnitude of the enhancement of intracellular delivery due to potentiator we've
plotted internalized cytotoxicity measurements for anti-CEA immunotoxins on HT-
1080(CEA) and HT-29 cells in the presence of CEA or EGFR potentiator
respectively alongside the curve-fit for unpotentiated TN5o from our previous work
(26) (Figure 3.8).
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Figure 3.7 - Potentiaion of internalized cytotoxicity and reduction of TNo.
Immunotoxins were fluorescently labeled and their internalization by antigen
positive cells was measured and quantified for the precise number of toxins inside.
In the absence of potentiator, ~5x10 6 toxins must be internalized on average before
a cell will undergo apoptosis. (A) HT-29 cells treated with independently non-toxic
levels of immunotoxin which shows concentration and time dependent
internalization in the presence of potentiator. (B) HT-29 cells treated with
equivalent doses show concentration and time dependent loss of viability. (C)
Combined data sets comparing loss of viability with respect to uptake indicates that
fewer than 5x10 3 immunotoxins were sufficient to induce apoptosis. The single
legend applies to all plots.
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Figure 3.8 - Combined potentiated internalized cytotoxicity. Internalized
cytotoxicity data from HT-1080, HT-1080(CEA) and HT-29 cells treated with
C7rGel and E6LLO are fitted to a dose response curve, but assay limitations
prevent determination of a potentiated TN5 o <104. This is compared to the
unpotentiated curve fit (26) with a TN5o of ~5x10 6. In the presence of potentiator,
significantly less immunotoxin uptake is required to induce loss of viability.
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3.4.5 - Delayed exposure cytotoxicity
Much like differential targeting of two antigens, we envisioned a system in
which two agents might be dosed independently in vivo to reduce non-specific
uptake of both agents simultaneously by antigen-negative cells. We tested the
possibility of this approach in vitro by treating cells for a fixed period of time with
growth media containing one agent, then removing it and replacing it with new
media containing the appropriate second agent. A431 cells were treated with anti-
EGFR E4rGel immunotoxin and then non-competitive anti-EGFR E6LLO
potentiator with increasing delay times (Figure 3.9A). Similarly, HT-29 cells were
exposed to differentially targeted immunotoxin (CEA) and potentiator (EGFR) at
order of magnitude higher concentrations, resulting in stronger but consistent
results (Figure 3.9B). Treatment concentrations for each agent were non-toxic
when exposed independently. For both cell lines, immunotoxin, and potentiator
combinations, potentiating activity was strongest for simultaneous exposure and
was abrogated as delay time increased but could still be observed even after 48
hours separation.
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Figure 3.9 - Delayed exposure potentiation of cytotoxicity. In these experiments
cells were exposed to a concentration of immunotoxin for 12 hours and a
concentration of potentiator for 24 hours with potentiator exposure starting at
either the same time (t= 0) or delayed by 12, 24, or 48 hours. (A) A431 cells treated
with E4rGel immunotoxin and E6LLO potentiator, both non-competitively targeting
EGFR. (B) HT-29 cells treated with C7rGel immunotoxin targeting CEA and
E6LLO potentiator targeting EGFR. We observe that potentiators can be effective
even after a 48 hour delay in treatments depending on concentration.
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3.5 - Discussion
The importance of targeted intracellular delivery to the advancement of numerous
therapeutic agents is well appreciated (3). While there has been some use of
cholesterol-dependent cytolysins in this area, our studies are the first to use
cytolysins as targeted in trans delivery agents together with a therapeutic that
targets a second, different cell-surface target. One benefit of this approach is that
targeting two independent antigens may improve in vivo tissue specificity.
Additionally, when two agents are delivered in trans, they can be dosed
independently, which can reduce unwanted side effects.
Our two agent approach was conceived of with the intention of directing a
biotherapeutic and a potentiator towards different antigen targets. While it may be
more convenient to target both components (i.e., the therapeutic agent, such as Fn3-
rGel, and a potentiating agent, such as Fn3-LLO or Fn3-PFO) to the same cell-
surface molecule, and while such a design would ensure colocalization, we were
interested in taking advantage of the additional specificity that targeting two
different antigens might confer in vivo. Prior to doing so we sought to confirm that
our two antigens of interest would colocalize within endosomes. We found that in
HT-29 cells, CEA and EGFR will colocalize. This is not entirely unexpected since
other cell surface antigens have been shown to colocalize (35) and most
internalization pathways converge in early endosomes (36). Moreover, scaling
analysis reveals that, in the absence of a preferential internalization mechanism,
two antigens are more likely to colocalize than not. Examining the current system
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where an average sized cell expresses -105 copies of either antigen per cell, if we
assume a random surface distribution of antigens and unbiased internalization,
then each endosome would contain -10 copies of each antigen, effectively ensuring
colocalization of any two targets.
We have described the synthesis of novel targeted fusion proteins
incorporating Fn3 and LLO or PFO. These fusions are expressed in E. coli and can
be readily purified. Fn3 clones affinity matured for binding EGFR and CEA
retained most of their affinity in the potentiator constructs, conserving nM binding
constants. In cytotoxicity tests these potentiators showed antigen specificity and
moderate cytotoxicity with IC5o's around 100 nM for LLO fusions and 10 pM for
PFO fusions. Analysis of the hemolytic activity of the fusions showed consistency
with previous reports of the different cytolysins' activity. LLO fusions showed
significant pH dependence and optimum activity at endosomal pH while PFO
fusions exhibited greater potency but limited pH dependence. The EC5o's at
physiological pH corresponded roughly with the non-specific cytotoxicity, while that
at endosomal pH was consistent with the antigen positive cell potentiating activity.
We proceeded to validate the ability of our Fn3-cytolysin to mediate increased
cytoplasmic delivery. When our immunotoxins targeting EGFR and CEA were
titrated in the presence of Fn3-cytolysin targeting the same antigen competitively
or non-competitively, or targeting an independent antigen, the immunotoxins
displayed IC5o's several orders of magnitude lower than in the absence of the
potentiating agent. Potency at these scales significantly improves the forecast for
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use of type I immunotoxins in the treatment of cancer. The degree to which potency
of a particular targeted biotherapeutic is enhanced by Fn3-cytolysin will be directly
tied to its inherent potency in the cytoplasm. We believe that these enhancements
in potency and selectivity will be broadly applicable to the delivery of any targeted
biotherapeutic without its own translocation mechanism.
Having established a metric for determining the relative barrier to
cytoplasmic delivery (26), we were interested in determining how Fn3-cytolysin
might lower this barrier. Fundamentally, our assay queries the integrity of
subcellular compartments in general, because it does not consider specific
subcellular localization and merely approximates cytoplasmic release with
cytotoxicity. Thus, an agent capable of enhancing the release of immunotoxin
through either pore formation or membrane destabilization should quantitatively
differentiate itself in this assay. We find that Fn3-LLO fusions are so effective in
this setting as to reach the lower limit of detection for the method. In fact, so few
molecules were required to be internalized prior to observing cytotoxicity that the
signal from the internalized immunotoxins did not surpass background fluorescence
of the cells. As a result we are forced to approximate the TN5 o for our
immunotoxins in the presence of potentiating Fn3-LLO fusions at less than 104
molecules. This shift in the TN5o value is consistent with the observed shifts in
cytotoxicity when compared to the TN5 o for our immunotoxins in the absence of
potentiator (~5x106).
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Our experiments showed the potentiation of our gelonin immunotoxins by
Fn3-cytolysin fusions also exposed their synergy against antigen negative cells.
This discovery further motivated us towards the use of delayed dosing in vivo. To
test the possibility of such an approach, we used a delayed exposure assay in which
cells were treated with immunotoxin for a fixed period of time followed by exposure
to a potentiating agent after increasing delay times. We found that at low
concentrations, a 48 hour delay between exposures was sufficient to abrogate
potentiated cytotoxicity, but that at higher concentrations, even on cells expressing
low levels of antigen, potentiation was still possible and even potent after the same
delay. These experiments suggest that, given a sufficient in vivo dose,
administration might be delayed by equally long times, which should be sufficient
for the first agent to be cleared from the plasma, thereby reducing simultaneous
exposure of antigen-negative cells subject to the highest concentrations of either
agent.
Notes - This chapter was reproduced in part from Pirie C.M., Liu D.V., Wittrup
K.D. (2011) Submitted.
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Chapter 4 - Pharmacokinetics and in vivo efficacy
4.1 - Abstract
There are an extensive number of in vitro assays available for characterization of
biotherapeutics, but there remains a set of critical pharmacokinetic traits that are
best, if not exclusively, determined by in vivo experimentation. We undertook a
rigorous assessment of the in vivo characteristics and therapeutic potential of our
independently-targeted intracellular delivery system. Maximum tolerated dose
escalation was performed for each drug, with CEA-targeted C7rGel showing no
limitations up to 16 mg/kg, and EGFR-targeted cytolysins E6LLO and E6PFO
having maximum doses of 0.6 mg/kg and 0.2 mg/kg respectively. The same
therapeutics were rapidly cleared with from the plasma: all agents had a-phase
half-lives from 30-120 minutes and 8-phase half-lives around 12 hours. These rates
are consistent with gelonin immunotoxin being cleared primarily by the liver and
cytolysin fusions being cleared primarily by the liver. We found that based on in
vivo imaging data and minimum dose separation experiments that a 6 hour
separation between immunotoxin and potentiator doses was optimal. Subcutaneous
tumor xenograft growth was inhibited and in fact regressed when treated with our
therapeutic combination. in vivo validation of this system further supports the
clinical potential of this approach. Future work should reveal whether this system
can be applied to alternative active biotherapeutics other than a plant toxin.
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4.2 - Introduction
Murine models of cancer have become standard practice in the progressive
assessment of promising therapeutics (1). Morevoer, the tumor xenograft model in
which human cancer cells are implanted into an immune compromised mouse has
been used consistently in pre-clinical development of new oncology drugs (2). As
scientific understanding of the complexity of biology continues to improve alongside
our ability to capture it through mathematical models, someday mouse models may
be replaced by computational models with better predictive capability for clinical
success. But until then we will continue to test new therapeutic strategies with
existing tools.
Tumor xenografts are the most common tool for in vivo testing of
immunotoxin efficacy. By selecting appropriate cell lines expressing the target
antigen, a wide array of immunotoxins can be tested (3-5). However, variations in
growth rate, mutation rate, and other phenotypes can drastically alter the
robustness of any xenograft study. Furthermore, the field lacks a consistent
standard with respect to beginning xenograft size or treatment regimen, making it
exceedingly difficult to compare the relative efficacy of immunotoxins in different
studies. Some of the key points to a rigorous xenograft experiment are addressed by
Seigall in his 1994 review (6): pointing out that vascularization is a key parameter,
suggesting that tumors between 50 and 100 mm3 are appropriate, and emphasizing
that treatment should be initiated not concurrent to tumor cell implantation but
rather sometime after the tumor has become established and vascularized. As
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many oncology drugs showing pre-clinical efficacy continue to fail in late-stage
trials, drug developers have focused on the fact that in xenografts tumor growth
inhibition is a necessary but not sufficient measure of success, instead, tumor
regression is the more relevant marker (7).
In recent years our group has become increasingly advanced in our use of
mouse models ranging from adoptive T-cells (8) to an array of different xenografts
(9, 10). Xenografts have been effective at allowing us to assess the pre-clinical
efficacy of various therapeutic modalities as well as the predictive or informative
powers of our pharmacokinetic biodistribution and tumor targeting models. We've
utilized that experience to interrogate the pharmacokinetics and in vivo efficacy of
our independently targeted intracellular delivery system to potentiate immunotoxin
activity against tumor xenografts.
4.3 - Methods
4.3.1 -in vivo model system
All in vivo studies used 6-8 week old athymic Ncr (nu/nu) nude mice obtained from
Taconic (Hudson, NY). This is the standard model for National Cancer Institute
studies and many pharmaceutical and oncology screening programs. Their outbred
background originates from BALB/c and NIH(s) stocks.
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4.3.2 - Large scale protein expression
Protein production required for in vivo experiments was accomplished using the
same protocol executed at 2L and 10L scales in Bioflo bioreactors (New Brunswick
Scientific, Edison, NJ) with oxygen control supplied by filtered air at 0.5 (vvm) and
agitation adjusted to maintain dissolved oxygen levels above 30%. pH was
controlled at 7.0 using 6N NaOH. Cells were grown to OD600 = 0.8 before induction
as before. Purification was carried out as described previously.
4.3.2 - Dose escalation
Dose escalation was carried out for all in vivo applied fusion proteins using the
canonical "3+3 method" in which 3 mice are dosed at a particular concentration and
if no dose limiting toxicity is observed then the dose is raised, if one of three mice
exhibit limiting toxicity then a new cohort of three mice are treated at the same
dose, and if two or more mice show limiting toxicity then escalation is stopped and
the previous dose is deemed the maximum tolerated dose. Here, in the absence of
any informed basis on which to select a starting dose, a logarithmically spaced
escalation was employed where after limiting toxicity was observed a linear
escalation was continued from the last tolerated dose.
4.3.3 - Plasma clearance
Fusion proteins were labeled with Li-Cor 800CW dye (Li-Cor Biosciences, Lincoln,
NE) by N-hydroxyl succinimide ester reaction with free amine groups. Labeled
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proteins were injected at their respective maximum tolerated doses into three mice
and blood samples taken at logarithmically spaced time points by tail clipping.
Blood was collected into heparin coated capillary tubes and imaged on a Li-Cor
Odyssey Imaging System (LiCor Biosciences). Imaging sensitivity was adjusted so
as to maximize signal-to-noise ratio without saturating the fluorescence channel.
Fluorescent signals were averaged across mice at each time point and fitted with a
bi-exponential function for retro-orbital injections and with a tri-exponential for
intraperitoneal injections to determining absorption and clearance constants as well
as plasma half-lives.
4.3.4 - Dose separation
Using clearance information as a basis we applied the same "3+3 method" as for
dose escalation to determine the minimum separation time between doses. Gelonin
immunotoxin was dosed first by retro-orbital injection at its independent maximum
tolerated dose. After the defined amount of time targeted cytolysin was dosed at its
own independent maximum tolerated dose either by retro-orbital injection in the
opposite eye or by intraperitoneal injection. Mice were monitored for toxicity for 72
hours following the second injection.
4.3.5 - IVIS Imaging
Therapeutic proteins C7rGel and E6LLO were labeled with the near-infrared
fluorophores Dylight 680 and Dylight 800 (Thermo Scientific, Rockland, IL),
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respectively, according to the manufacturers' instructions. Maximum tolerated
doses of both proteins were administered by retro-orbital injection at a separation
time of 24 hours. While under anesthesia, HT-29 tumor bearing mice were imaged
periodically on an IVIS 200 Imaging System (Caliper Life Sciences, Hopkinton, MA)
across a range of excitation and emission bandwidths to allow for spectral
deconvolution. Images were taken with greater frequency immediately following
each injection. Mice with variable tumor sizes were used to account for differences
in the size of the antigen sink provided by the tumor. Regions of interest were
drawn around tumors and opposing flanks without tumors and radiant efficiency
(photons/cm2/sec) was used to quantify the relative amount of each drug in the
tumor versus elsewhere in the mice.
4.3.6 - Tumor xenograft growth inhibition
Mice received subcutaneous injections of 3x10 6 HT-29 cells in the right flank on day
0. Digital caliper measurements to determine tumor volume were begun on day 7
and taken every other day for the duration of the study. On day 7 measurements
were used to divide mice into treatment groups to balance the average tumor
volume for each group. Four groups were used: phosphate buffered saline
(PBS)/PBS, C7rGel/PBS, PBS/E6PFO, and C7rGel/E6PFO as primary/secondary
respectively. Treatments in the study were given on day 7 and 11 with 3 hour and 6
hour separations between primary retro-orbital injection and secondary
intraperitoneal injection.
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4.3.7- Histology and immunofluorescent staining
At various time points, mice were euthanized and their HT-29 xenografts removed.
Tumors were then frozen in plastic cartridges filled with Tissue-Tek O.C.T.
Compound (Sakura Finetek USA, Torrance, CA). To freeze at the appropriate rate,
cartridges containing freezing compound and a suspended tumor xenograft were
placed in a bath of 2-methylbutane (Sigma-Aldrich, St. Louis, MO) which was then
placed in a bath of liquid nitrogen until the freezing compound turned an opaque
white. Cartridges were store at -80 *C until sectioned into 8 Rm slices at the Koch
Institute Swanson Biotechnology Center. Haematoxylin and eosin (H&E) staining
was also performed by the Center and unstained slides containing tumor sections
were provided and used for immunofluorescent staining. H&E images were taken
by a digital camera adapted to a Zeiss Axiovert 40c with a 20x lens.
To stain, frozen slides were thawed for 30 min at room temperature. A pap
pen was used to draw a border around the entire slide. Cells were fixed with a 5%
formalin solution in phosphate buffered saline (PBS) for 10 min. Slides were then
washed repeatedly with PBS. A blocking solution of 5% goat serum in PBS was
applied to the cells for 1 hr. Primary antibodies against either CD-31 (BD
Biosciences, Franlin Lakes, NJ), a vascular marker, and/or cleaved caspase-3 (Cell
Signaling Technology, Danvers, MA), an apoptosis marker, were diluted 1:100 in
PBS with 5% goat serum and incubated on slides overnight at 4 0C. Again cells
were washed repeatedly with PBS and then secondary antibodies specific to the
species of the respective primary antibodies were diluted 1:200 in PBS with 0.1%
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Tween 20 detergent and incubated for 1 hr at room temperature. More PBS washes
were conducted before slides were mounted with Vectashield Mounting Medium
with DAPI (Vector Laboratories, Burlingame, CA) and a coverslip then sealed with
clear nail polish. Images were taken under 10x or 60x magnification on an inverted
Olympus X71 Deltavision deconvolution microscope.
4.4 - Results
4.4.1 - Independent dosing and clearance
Nude mice were dosed by the "3+3 method" with increasing amounts of either
gelonin or cytolysin immunotoxins until dose limiting toxicity was observed. For
CEA-targeted C7rGel no substantial toxicity was observed up to doses of 16 mg/kg
while for E6LLO and E6PFO dose limiting toxicities were reached above 0.6 and 0.2
mg/kg respectively (Table 4.1).
We evaluated plasma half-lives of our therapeutic proteins to better inform
dose separation. Bi-exponential fitting of protein clearance data from retro-orbital
injections yielded alpha-phase half-lives and beta-phase half-lives of 30 minutes and
12.2 hours for C7rGel, 124 minutes and 11.5 hours for E6LLO, and 34 minutes and
13.3 hours for E6PFO. Tri-exponential fitting of data from intraperitoneal
injections revealed a plasma absorption half-time of 65 minutes. Examples of
clearance data and curve fitting results are provided (Figure 4.1)
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0.02 0/3
0.08
0.2
0.8
0.4
0.6
0/3
0/3
2/3
0/3
0/3
0.08 0/3
0.2 0/3
0.8
0.4
3/3
2/3
Table 4.1 - Independent dose escalation of therapeutic proteins. The "3+3 method"
was used to assess dose limiting toxicities as each agent to be used for in vivo
testing was administered at increasing levels. We found that for C7rGel substantial
doses could be given without toxicity but that for E6LLO and E6PFO the maximum
tolerated dose was less than 1 mg/kg.
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Figure 4.1 - Plasma clearance of immunotoxin and potentiators. Proteins used for
in vivo testing were labeled with infra-red dye and injected into groups of three
mice. Blood samples were collected at logarithmically spaced time points from the
tail. (A) C7rGel injected retro-orbitally. (B) E6LLO injected retro-orbitally. (C)
E6PFO injected intraperitoneally.
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4.4.2 - Biodistribution and tumor targeting
Near-infrared imaging of mice allowed us to track the biodistribution and clearance
mechanism of both C7rGel and E6PFO. Images taken within the first 8 hours
following retro-orbital injection of C7rGel exemplified the primary renal clearance
of the ~40 kDa therapeutic. At later time points the liver and bladder also showed
elevated levels of the gelonin immunotoxin. Data from region of interest analysis
show that the maximum fluorescent signal in the tumor is achieved between 20 and
60 minutes after injection (Figure 4.2A). Tumor fluorescence signals were divided
by radiant efficiency data from an identical region on the opposite flank giving a
tumor to skin ratio. In contrast to the direct tumor signal, the ratio was highest
approximately 4 hours after the injection, likely due to the more rapid clearance of
the therapeutic from the plasma compared to the tumor (Figure 4.2B).
Whole animal images were taken 8 hours following injection of labeled
gelonin immunotoxin show distinct tumor localization dependent on tumor volume
(Figure 4.3A). Two hours after injection of labeled, targeted cytolysin we observed
strong signal from the liver implicating it as the primary clearance organ but fail to
mimic the differentiable tumor retention of C7rGel (Figure 4.3B).
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Figure 4.2 - IVIS imaged tumor accumulation of gelonin immunotoxin.
radiant efficiency from regions of interest drawn around tumors. (B)
dependent ratio of radiant efficiency from tumors and opposing flank.
(A) Total
Time
96
A
0
CU
U)
E
i
C
U)
AB
Figure 4.3 - Spectral deconvolution of IVIS images. (A) Dylight 680 labeled C7rGel
biodistribution 8 hours after retro-orbital injection. Primary signal areas are
injection sites, tumors (right flank), and what is likely the gallbladder. (B) Images
taken 2 hours after injection of Dylight 800 labeled E6PFO show a similar
distribution of C7rGel but a lack of tumor localization of the targeted cytolysin and
primary liver clearance.
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4.4.3 - Combina tion treatment of tumor xenografts.
Dual agent treatment was performed initially with retro-orbital injection of both
agents with C7rGel injected first and E6LLO or E6PFO injected second. We shrank
separation time linearly, again using the "3+3 method" until dose separation
limiting toxicity was observed. Results indicated that when using this route of
administration E6LLO could only be dose no sooner than 12 hours after C7rGel
injection and the minimum delay with E6PFO was 24 hours (Table 4.2). Based on
these limitations and our understanding of the clearance rate of C7rGel, we
investigated the possibility of intraperitoneal injection of targeted cytolysins
secondary to injection of gelonin immunotoxin. We hoped that like injection of other
protein therapeutics into the peritoneal cavity we might be able to achieve a more
gradual uptake into the plasma while gelonin immunotoxins were still residing in
the tumor (11). When administering C7rGel by retro-orbital injection followed by
intraperitoneal injection of targeted cytolysin we found that E6LLO and E6PFO
doses could follow as little as 6 hours after (Table 4.2).
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-0/3 18 0/3 12-0/3 6-3/3
24 - 0/3 18 - 2/3 - - -
- - - 6-0/3 3-1/3
24-0/3 18-0/3 12-0/3 6-0/3 3-2/3
RO = Retro-orbital
IP = Intraperitoneal
Table 4.2 - Determining minimum delay between doses of synergistic agents. When
administering by retro-orbital injection which results in an almost instantaneous
maximum plasma concentration we found that subsequent doses required at least a
12 hour delay. Alternatively when we administered secondary injections of targeted
cytolysins into the peritoneal cavity where absorption into the plasma was slowed,
we found that doses could be given with as little as 3 hours delay.
Once we had determined the maximum tolerated dose and minimum dose
separation time we used these to test for efficacy in a tumor xenograft model. Nude
mice bearing established HT-29 colorectal carcinoma xenografts were dosed with
PBS & PBS, C7rGel & PBS, PBS & E6PFO, or C7rGel & E6PFO. Control groups
were run in parallel to confirm that neither C7rGel, nor E6PFO alone could control
tumor growth. Individual therapeutic treatments resulted in no reduction in the
logarithmic growth rate of the xenografts, and no statistically significant difference
between mean tumor volumes (Figure 4.4).
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Figure 4.4 - Individual therapeutic tumor control impotency. C7rGel or E6PFO
dosed twice at their respective maximum tolerated dose was incapable of controlling
tumor growth when compared to a PBS control group growth. Legend applies to
both plots. (A) Tumor volume measurements over the course of the study and (B) a
semi-log representation of the data to convey logarithmic growth rate.
In contrast, when we dosed mice with a retro-orbital injection of C7rGel and
an intraperitoneal injection of E6PFO separated by 3 hours on day 7 and 6 hours on
day 11, we observed a statistically significant reduction in tumor volume and
growth rate (Figure 4.5A/B). Unfortunately, one of three mice had to be sacrificed
at day 13 due to treatment related morbidity, but we did attain a durable response
in one of the two remaining mice (Figure 4.5C). Recurrent rounds of treatment
appear to have had a cumulative toxicity effect not observed in preliminary dose
limiting experiments. Repeated measures ANOVA of PBS versus combination
treatments yield a P-value of 0.053 and an F-value of 9.71.
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Figure 4.5 - Synergistic combination therapy. Treatment with our therapeutic
combination resulted in (A) a reduction of the average tumor volume and during
treatment; (B) tumor growth rate is not just stabilized, but in fact showed
regression.(C) The growth curves of individual mice in each group are very
consistent for PBS treated mice, but treatment related toxicity and inconsistent
responses across the combination group cause the large error observed.
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Histological analysis of control and treated tumors are rather remarkable.
H&E images show distinctive loss of healthy morphology and gross physiological
changes compared to untreated tumor samples (Figure 4.6). Tumors were excised
24 hours after initial injection. Sections from the same tissue sample were labeled
by immunofluorescence for the apoptosis marker cleaved caspase-3 and images
showed strong cellular staining (Figure 4.7A). When mice given injections of
fluorescently labeled immunotoxin and cytolysin fusion under standard dosing
conditions were euthanized 2 hours after cytolysin injection, tumor
immunofluorescence indicated the continued presence of both agents in capillaries,
colocalizing with a CD31 stain, while also showing strong cellular association and
combined colocalization measured by a strong Pearson's coefficient.
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AFigure 4.6 - HT-29 xenograft H&E staining. (A) Healthy tumor cells treated with
PBS display good cell-cell connections, large nuclei, and blood vessels. (B) Tumor
cells treated with C7rGel and E6PFO have classical apoptotic phenotypes with
rounded morphology and DNA condensation (small nuclei). Fragmentation is
difficult to observe at this magnification.
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AFigure 4.7 - Immunofluorescence of apoptosis and dual agent exposure. (A) Two-
color fluorescence of apoptotic marker cleaved caspase-3 (green) and capillary
endothelial marker CD31 (red) under 10x magnification. The majority of tumor
cells show strong apoptotic signal. (B) Four-color fluorescence of CD31 (red), nuclear
staining with DAPI (blue), Alexa Fluor 647 labeled C7rGel (white), and Alexa Fluor
488 labeled E6PFO (green) under 60x magnification.
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4.5 - Discussion
The canonical progression from therapeutic development to clinical trials is based
on pre-clinical studies in animal models that move from mice to a non-human
primate. And while many drugs that show early success in vivo fail at various
points in the process thereafter, this is still the standard approach. Here, we've
taken the first steps towards proving the clinical potential of our independently
targeted intracellular delivery system.
Results of independent therapeutic dose escalation were consistent with our
expectations as informed by in vitro studies and historical use of these same agents
in vivo. Rosenblum et aL. dosed scFv-gelonin as high as 20 mg/kg (12), Geoffroy et
aL. found the 50% lethal dose of LLO to be 0.027 mg/kg (13), and it has been shown
that PFO has the same specific activity as LLO but without any time-dependent
inactivation at neutral pH suggesting that it's MTD should be lower (14). It was
this inactivation property that urged us towards the use of PFO fusions for our
preliminary tumor xenograft experiments because we were concerned that E6LLO
would be inactivated at the neutral pH of the plasma before reaching the tumor,
binding, and internalizing. The relative dosing limits found here are consistent
with the in vitro and in vivo work of others with these proteins, even if their
absolute values differ somewhat. Those differences may be attributable to
difference in molecular weight of our targeted fusion proteins (when considering
mg/kg) or possible destabilization of the native cytolysin folding resulting from
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incorporation in the fusion construct similar to that observed for the binding of our
Fn3's and scFv's or the toxicity of gelonin in fusions.
Differences in plasma clearance rates between fusion proteins correlated with
molecular weight as expected for C7rGel and E6LLO, but for E6PFO we measured a
much more rapid clearance rate that may be due to interactions with circulating cell
or endothelial cell membranes leading to active clearance beyond normal filtration
or hepatocellular uptake. Using intraperitoneal injection as an alternative to retro-
orbital injection and as a way to control plasma uptake, E6PFO was able to
intravasate, but it is difficult to assess from these data precisely what percentage of
IP dose becomes bioavailable. Both absolute dose and the volume of injection will
likely play a part in the degree of bioavailability (11) adding yet another variable
that should be optimized as this therapeutic approach is further developed.
IVIS imaging was utilized as one way to address whether both agents were
capable of being localized and retained in tumor xenografts. In these experiments
fluorescently labeled C7rGel localized to tumors and was retained there longer than
in naive, non-specific tissues. However we were unable to show any tumor-specific
localization or retention of E6PFO. It is possible that this is a result of the
drastically lower dose of E6PFO relative to C7rGel not generating a strong enough
signal (-100x molar difference in dose) although the primary clearance organ does
produce a strong signal even at this dose.
When shrinking the separation time between doses, minimum separation
times for retro-orbital injection of both agents correlated with the potency of the
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respective targeted cytolysin. Intraperitoneal injection of targeted cytolysin allowed
for shorter separation times, likely attributable to the slower time to maximum
plasma concentration and perhaps lower overall bioavailability. Interestingly, the
minimum delay for either cytolysin fusion by this administration route was the
same despite their differences in independent potency and toxicity.
One of the primary motivations for developing this therapeutic approach was
the inability of our immunotoxins targeted against either carcinoembryonic antigen
or epidermal growth factor receptor to mediate antigen-dependent cytotoxicity
against the HT-29 cell line in vitro. Thus it is not surprising that, even when given
at quite a high dose, C7rGel is unable to inhibit tumor growth in a xenograft model
using the same cells. The result is also consistent with predictions made in our
pharmacokinetic model (Chapter 5) with respect to the number of internalized
immunotoxin molecules relative to the previously defined threshold for induction of
apoptosis (Chapter 2). From a clinical perspective, not all tumors that over express
a particular antigen will do so at a level necessary for independent activity of
immunotoxin, therefore a system that can induce targeted cytotoxicity against cells
expressing tumor antigens at only modest levels is desirable.
The high toxicity of E6PFO might be expected to yield some independent
tumor xenograft control, but our results show that it does not. This might be due
again to a loss of significant amounts of the dosed material to non-specific
membrane interactions. It is clear that at least a minimally potentiating
concentration of targeted cytolysin does reach the tumor because of the significant
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synergistic activity observed in combination as controlling of tumor xenograft
growth. Despite the mixed results of tumor xenograft control, we are encourage by
the follow up histology which showed that combination treated tumors resulted in
colocalization of both therapeutics in the tumor interstitium and induction of
widespread apoptosis. Anecdotally, we observed that induction of apoptosis
depended on the size of the tumor being treated. These very preliminary in vivo
therapeutic efficacy experiments provide a hint of the potential of this approach but
also serve to emphasize the substantial amount of work that remains to be done to
fully harness that potential.
Notes - This chapter was inspired by Pirie C.M., Liu D.V., Wittrup K.D. (2011)
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Chapter 5 - Pharmacokinetic modeling of combination therapy
5.1 - Abstract
Use of computational models can provide insight into complex biological
systems. Here we use a two-compartment deterministic model to address the
difficulty of simultaneously monitoring the multitude of variables that might be
present in a particular in vivo experiment. Pharmacokinetic parameters were used
as inputs and the time dependent levels of numerous molecular species or
complexes of interest were tracked. Exposure of the tumor compartment to
immunotoxin was simulated and depended on the dose separation time and route of
administration of potentiating agent. Tumor overlap exposure varied by as much as
20% under different dose limiting conditions in vivo. At toxicity limited doses of
immunotoxin, endothelial cell internalization does not appear to be a source of
toxicity and depending on the average separation between capillaries in the tumor,
the average tumor cell internalizes only enough immunotoxin to overcome the
potentiated threshold for apoptosis. These results support particular dosing
regimens for future in vivo studies and provide insight into the possible sources of
dose limiting toxicity for gelonin immunotoxins.
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5.2 - Introduction
Mathematical modeling continues to gain traction in the biological sciences,
where its uses range from structural protein-protein interaction models (1) to
cellular level systems modeling (2, 3) to physiological models of pharmacokinetics
(4, 5). As this trend develops we may begin to see more and more experimental
effort replaced by validated models with reliable predictive capabilities. In fact, the
FDA has even begun accepting model based data to accompany, and in some cases
replace, pre-clinical data (6, 7). Compartmental models, consisting of well-mixed
"compartments" representing organs or tissues of the body can be useful for
simplification of the otherwise complex process of biodistribution. When an agent's
movement into and out of a compartment is defined by kinetic rate parameters,
then the instantaneous or time dependent amount of that agent in each
compartment can be calculated.
Others have used mathematical models to investigate immunotoxin
properties on both physiological and cellular scales. One of the earliest examples is
Sung et aL. who modeled the tumor distribution and cell surface binding of blocked
diphtheria toxin and a transferrin receptor binding antibody based immunotoxin
thereof (8). Much of the related work has been done in the Murphy Lab at the
University of Wisconsin. For almost a decade their studies addressed immunotoxin
binding, internalization, and translocation not unlike our own initial work (Chapter
2) and their models predicted translocation kinetics that were supportive of our
experimental results (9-12). The most recent model developed by Chen et aL.
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combines tumor distribution and cellular kinetics resulting in model predictions of
tumor xenograft growth inhibition (13).
Ideally, a model describing the dosing, pharmacokinetics, and tumor
biodistribution of two independently targeted protein therapeutics would inform in
vivo experiments to eliminate much of the costs associated with such work (namely
animal life). But the complexities of in vivo systems are such that it can be quite
difficult to execute representative in vitro experiments the results of which can be
used to validate and support model outputs. As we strove to characterize the
fibronectin targeted fusion proteins to gelonin and cholesterol-dependent cytolysins,
we lacked appropriate in vitro systems to address or even query limits of in vivo
toxicity or putative efficacy. In this modeling work we focused on the same set of
therapeutics that we used for in vivo efficacy experiments. These therapeutics
consisted of a primary treatment of carcinoembryonic antigen-targeted gelonin
immunotoxin (C7rGel) followed by a secondary treatment with a potentiating
epidermal growth factor receptor-targeted cholesterol-dependent cytolysin (E6LLO
or E6PFO), against a cell line expressing only modest levels of either antigen.
Our model builds upon the foundational work in the group conducted by
Thurber, Schmidt, and Wittrup (14, 15). Their compartmental model strove to
analyze the limitations to antibody transport in tumors and to assess the effect of
molecular size on tumor biodistribution. Here, we build upon the principles they
established in understanding biodistribution of antibodies and antibody fragments
and apply them to the biodistribution of our fusion proteins and the effects it has on
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dosing and compartmental colocalization of two different targeted proteins in
tumors.
5.3 - Methods
5.3.1 - Core model
Original MATLAB (The Mathworks, Natick, MA) code for a compartmental,
Krogh cylinder model describing the pharmacokinetics and tumor biodistribution of
antibodies was graciously provided by Dr. Michael Schmidt. Briefly, the
fundamental equations of that code describe the diffusivity of protein out of the
capillary as a two-pore system, the tumor void fraction using the same self-
consistent representation, the resulting size-dependent permeability of the capillary
to the protein, clearance of protein from the bloodstream as a single exponential
with a rate proportional to renal and non-renal clearance rates. From those inputs,
uptake into the tumor interstitial space, and the time to maximum therapeutic
concentration in the tumor were calculated (16, 17). This code was used as a basis
for the modifications described herein (Figure 5.1).
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Figure 5.1 - A multi-compartment dual therapeutic model. Modified from Schmidt
et aL., concentrations of therapeutic protein and other species in different
compartments are monitored: Cb (in blood), Ct (in tumor), Cs (bound), Ci
(internalized), and Ca (antigen concentration). P is the capillary permeability, Rcap
is the capillary radius, RKrogh is the Krogh cylinder radius, e is the tumor void
fraction, kon and koff are the binding rates for the antigen/protein interaction, ke is
the endocytosis rate, A and B are the clearance fractions, a and 8 are the clearance
rates, and ka is the absorption rate. Two different equations are provided for either
accumulation or removal from the blood stream depending on the route of
administration.
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5.3.2 - Model parameter determination
In some cases, model parameters we determined empirically from data
collected in previous chapters. Many parameter values were derived from the
online calculator designed in our lab (http://tumormodel.org/) (17). When necessary,
parameters were obtained from literature sources which are cited where
appropriate.
5.3.3 - Clearance equations
Where in the core model a single exponential clearance equation had been
used we built in a bi-exponential equation:
Cb = Cmax(Ae-at + Be- 3 )
where A, B, a, and B were fitted to experimental plasma clearance data measured
from mice injected retro-orbitally. And tri-exponential:
Cb = Cmaxka(Ae--1 + Be-2I - (A + B)e-kat)
where A, B, X1, X2, and ka were fitted to experimental data from intraperitoneal
injections. These equations more accurately represent and use parameters
coordinated with in vivo data collected (Chapter 4) following either retro-orbital or
intraperitoneal injections, respectively.
5.3.4 - Dual agent dosing
To most accurately represent our in vivo system and develop a model with
the most clinical relevance, it was important to build in the delayed dosing
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approach we used experimentally. In the computational setup this was achieved by
iterating the model with a time shift to simulate dual retro-orbital injections and to
replace the simple bi-exponential decay rate in the plasma with a tri-exponential
plasma concentration equation in the delayed iteration, to simulate a secondary
intraperitoneal injection.
Time delays used in the model were based on the minimum dose separations
that were determined empirically (Table 5.1). We ran simulations of dual retro-
orbital injections for C7rGel primary and for either E6LLO or E6PFO secondary.
For secondary intraperitoneal injections we only simulated E6PFO.
Table 5.1 - Secondary time shifts for simulations
Secondary (Route) Time shift (hrs)
12
24
6
5.3.5 - Calculation of tumor exposure overlap
From a physiological perspective one of the most important goals of this
approach is to achieve the maximum tumor exposure to both agents in combination
without such exposure to the vascular endothelium. To quantify the strength of
dual exposure, we calculated the area under curve (AUC) for immunotoxin in the
tumor interstitial space while in the presence of potentiator for each dosing
condition. This was achieved using the cumulative trapezoidal method in MATLAB
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E6LLO (retro-orbital)
E6PFO (retro-orbital)
E6PFO (i ntra peritonea1)
( Z = cumtrapz(Y) ) to get an integral approximation for each agent across time
increments at which the concentration of the potentiator was non-zero.
5.3.6 - Endothelial versus tumor internalization
Internalization of immunotoxin by both capillary endothelial cells and tumor
cells was modeled. Antigen dependent internalization was a component already
incorporated into the core model but in order to address cumulative uptake we had
to remove the signal decay component originally used to describe the loss of
scintillation signal over time. Furthermore, to obtain a quantitative measure of the
average uptake per cell across a tumor cross section, it was necessary to
approximate the number of cells within the computationally simulated cross-section
of the Krogh cylinder radius. We first defined the volume of the cross-section:
V = dceui X w(router - Tinner 2
based on the diameter of an average cell (dce) and the cross-sectional radii (router
and rinner) and approximated then the number of cells (Ncenis) in that cross section as
a generalization from the average cell density of a tumor (ptumor) in cells/volume
Nceis = V X Ptumor
From there the average number of therapeutic molecules internalized by each cell
(Ni) was calculated from volume, the internalized concentration (Ci) output from the
core model, Avogadro's number (Nay), and Ncens:
= Ci VNav
Nceis
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In the case of antigen-negative cells, specifically those of the vascular
endothelium, we approximated non-specific uptake (U) by integrating the plasma
concentration of the therapeutic over time and multiplying it by a generalized
pinocytic uptake rate (ku) :
t
U = ku fo C dt
Internalized molecule calculations were compared to measurements of
molecular cytotoxicity in vitro (Chapters 2/3).
5.4 - Results
5.4.1 - Parameter assignment
Model parameters that were not dependent on the particular biotherapeutic
used are listed and when determined from the literature, citations are provided
(Table 5.2). For tumor radius, which here refers to the same dimension as the
Krogh cylinder, we reference two citations but also base the number on work in our
own group using immunofluorescence and advanced image analysis to determine
the median distance between capillaries in tumor xenografts.
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Table 5.2 - Parameter values independent of protein characteristics
Endothelial pinocytosis rate
Antigen endocytosis rate
Effective antigen concentration
Tumor radius
Capillary radius
Tumor cell density
ke (CEA)
ke (EGFR)
Ca
RT
Rc
Ptumor
23x10 15 L/hr
3x10-5 s
1.5x10-s s-1
550x10~9 M
150x10'6 m
8x10~6 m
7X10 8 cells/mi
Additional parameters for individual agents dosed in vivo were obtained from
primary data, literature, or other sources (Table 5.3). Here, all clearance
parameters were taken from infra-red labeled protein measurements in plasma
samples collected as described (Chapter 4). The rather rapid clearance of these
therapeutic proteins is likely a result of their relatively small size. At 40 kDa,
fibronectin targeted gelonin is within the glomerular filtration cut-off and, as we
observed in whole animal imaging, is cleared primarily by the kidneys. In contrast,
E6LLO has a slightly longer half-life and both it and E6PFO are cleared primarily
by the liver.
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(18)
(19)
(20)
(21, 22)
(23,24)
(25)
(18)
Table 5.3 - Parameter values specific to individual therapeutics
Parameter SyblValueRernc
M ~C7rGel / E6LLO- / E6PFO
Dose Cmax]
Antigen binding on rate kon
Antigen binding off rate km
Capillary permeability P
Tumor diffusivity A
Tumor void fraction E
Plasma alpha fraction A
Alpha decay rate a
Plasma beta fraction B
Beta decay rate @
IP intravasation rate ka
IP primary coefficient L
IP lambda primary A
IP secondary coefficient L2
IP lambda secondary A2
4.5x106 / 1 .3X10 ~7 2x10 (M)
5x10s (M-' s~ )
10-3 / 2.5x10~3 / (s-1)
6.73 / 5.03 / 5.18 (x10V cm/s)
5.7 / 4.11 / 4.29 (x10 7 cm2/s)
0.319 / 0.287 / 0.291
0.82 / 0.85 / 0.95
0.023 / 0.0056 / 0.02
0.18 / 0.15 / 0.05
0.00095 / 0.00099 / 0.0009
- / - / 0.0106 (min')
- / - / 8.95
- / - / 0.0089
- / - / 0.39
- / - / 0.00048
*
(26)
t1
*
*
*
*
*
*
*
*
*
*
*
*
* Determined by empirical measurement
t Ka's were measured (Chapter 3) and koff= kon*Ka
* Obtained from online tumor uptake predictor (tumormodel.org)
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5.4.2 - Plasma clearance and tumor targeting
Simulations accurately reproduced the plasma clearance kinetics measured
in vivo for both retro-orbital and intraperitoneal injections (Figure 5.2). Consistent
with in vivo data, the model reproduced the rapid clearance of each different
therapeutic from the plasma after retro-orbital injection with characteristic bi-
exponential curves. After intraperitoneal injection the plasma concentration
remains elevated for a greater duration due to the slow intravasation from the
peritoneal cavity.
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Figure 5.2 - Simulation of biotherapeutic plasma concentration.
clearance following retro-orbital injection of C7rGel, (B) E6LLO, or (C)
(D) following intraperitoneal injection of E6PFO.
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5.4.3 - Dual dosing and exposure calculations
To better understand how dosing schedules and schemes influence the
exposure of either vascular endothelium or tumor to both therapeutics
simultaneously, we simulated dual agent dosing and monitored the plasma
concentrations (Figure 5.3) and the tumor concentrations (Figure 5.4). A common
theme amongst these simulations, which is consistent with in vivo results is the
rapid appearance of therapeutic in either the plasma or tumor interstitial space
following retro-orbital injection and the relatively longer time to achieve maximum
concentration in those same compartments for therapeutic injected into the
peritoneal cavity.
From these simulations we also quantified overlap of immunotoxin and
potentiator in the tumor interstitial space. AUC calculations of C7rGel across times
of dual exposure for 6, 12, or 24 hour separation times were 4.92x10-7, 4.66x10-7,
4.09x10-7 M -hrs, respectively. This result suggests that by using alternative routes
of administration that allow for shorter separation times we can increase
overlapping exposure in the tumor by twenty percent.
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Figure 5.3 - Modeling therapeutic overlap in the plasma. Combination treatments
are simulated on arbitrary scales with different dose separations and routes of
administration. C7rGel concentration is plotted in blue and potentiator
concentration is plotted in red. (A) E6LLO retro-orbital injection with 12 hour
delay. (B) E6PFO intraperitoneal injection with 6 hour delay.
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Figure 5.4 - Therapeutic concentrations in the tumor interstitium. Simulated tumor
overlap for C7rGel (blue lines) and potentiator (red lines) with either (A) E6LLO by
retro-orbital injection after 12 hour delay or (B) E6PFO by intraperitoneal injection
after 6 hour delay.
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5.4.4 - Internalization by vascular endothelium and tumor cells
As is generally accepted in the field and known intimately to us from our
earliest investigations of immunotoxin activity, potency is intimately tied to
internalization (27, 28). Ultimately, it is internalization that leads to cytotoxicity,
whether targeted or non-specific. To this end, we sought to capture the
accumulated number of internalized molecules by cells in the vascular endothelium
and tumor. Like our dose overlap calculation, we focused on internalization
occurring after dosing of the potentiation agent. We found that fewer than 200
molecules of immunotoxin are pinocytosed by cells of the vascular endothelium
while the average tumor cell internalizes 3.1x10 6 molecules. This number is just
under the -5x1O 6 internalized molecule threshold for apoptosis determined in our
earlier work (Chapter 2) but well above the ~104 molecule threshold found in the
presence of a potentiating cytolysin (Chapter 3). It is important to note however the
strength of the relationship between tumor cell internalization of immunotoxin and
the Krogh cylinder radius. The calculation represents an average internalization
meaning that cells near the capillary likely internalize a greater number and there
are cells that don't internalize nearly as many. When Krogh cylinder radius is
varied between 50 and 200 gm there is a non-linear effect on the tumor cell
internalization of immunotoxin ranging from 2.3x10 7 to 2x10 6.
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Figure 5.5 - Immunotoxin uptake simulation. Model outputs for internalization in
(A) the vascular endothelium and (B) by tumor cells. Outputs were considered
surrogates for non-specific toxicity and efficacy in vivo. The red and blue lines
represent the thresholds for internalized cytotoxicity in the presence or absence of
potentiator.
5.5 - Discussion
Building upon the pioneering work of others from our group (17, 18) we have
been able to characterize the basic pharmacokinetics of our two novel therapeutics
in a two-compartment model system. Our mathematical modeling was both
informed by and motivated in vivo experimentation (Chapter 4). We supplemented
empirically determined model parameters where necessary with metrics derived
from literature sources. Results indicated that in the situation in which E6PFO
was used as the potentiating agent and administered by intraperitoneal injection,
the allowed shorter delay time increased the amount of immunotoxin available in
the tumor to be potentiated by approximately 20% over the dual retro-orbital
injection strategy.
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Remarkably, increased overlap in the plasma following intraperitoneal
injection of potentiator does not result in increased morbidity. Our hypothesis had
been that combination therapeutic toxicity in vivo resulted from non-specific uptake
of both agents by vascular endothelial cells, but this modeling result suggests that it
may arise from common clearance organs internalizing both agents. If we recall our
whole animal imaging results (Chapter 4), it seems clear that such toxicity would
have to arise in the liver or one of the secondary clearance organs. Unfortunately,
the current model does not simulate hepatocellular uptake of immunotoxin.
When we take overlap in exposure a step further to consider the cumulative
internalization of immunotoxin by cells either of the vascular endothelium or of the
tumor, we find that thanks to antigen specific binding, a vastly greater number of
immunotoxins are internalized by tumor cells. That internalization is insufficient
on average to induce cytotoxicity in the absence of potentiator, but more than
overcomes the threshold for apoptosis in the presence of potentiator. The
potentiator itself is also internalized at significant levels, but without supporting in
vitro data correlating uptake with cytotoxicity it is impossible to predict the impact
of these particular levels. The influence of the Krogh cylinder radius parameter on
tumor cell internalization of immunotoxin is quite significant; for physiologically
relevant ranges, changes to the Krogh cylinder parameter can cause the average
number of immunotoxins internalized to be either above or below the apoptotic
threshold in the absence of potentiator.
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Despite these promising conclusions derived from our mathematical model, in
vivo experiments show that repeated doses at the levels described here result in
varying levels of toxicity. This further supports the idea that in vivo toxicity is the
result of clearance organ damage rather than vascular leak syndrome which is a
common dose limiting toxicity in clinical trials of immunotoxins (29, 30). Others
have found toxicities associated with elevated transaminase levels (usually
correlated with liver damage) following immunotoxin treatments (31, 32) which are
likely to be accentuated when subsequently dosing with a potentiating agent whose
primary clearance organ is the liver.
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Appendix A - Amino acid sequences of proteins
Chapter 2
A. 1 - rGel (recombinant gelonin)
ISEFGSSRVDLQGLDTVSFSTKGA T YITYVNFLNELRVKLKPEGNSHGIPLLRKK
CDDPGKCFVLVALSNDNGQLAEIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEG
LFKNTIKTRLHFGGSYPSLEGEKAYRETTDLGIEPLRIGIKKLDENAIDNYKPTEI
ASSLLVVIQMVSEAARFTFIENQIRNNFQQRIRPANNTISLENKWGKLSFQIRTSG
ANGMFSEAVELERANGKKYYVTAVDQVKPKIALLKFVDKDPK
A.2 - C7rGel (anti-CEA Fn3 - recombinant gelonin)
ISEFASVSDGTLSRDLGVVAATPTSLLISWYYSYSHHYSSYRITYGETGGNSPVQE
FTVPRYRAFATISGLKPGVDYTITVYAVTSSSSYSYPISINYRTEIDKPSQGSGGGG
SGLDTVSFSTKGATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCFVLV
ALSNDNGQLAEIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLHF
GGSYPSLEGEKAYRETTDLGIEPLRIGIKKLDENAIDNYKPTEIASSLLVVIQMVS
EAARFTFIENQIRNNFQQRIRPANNTISLENKWGKLSFQIRTSGANGMFSEAVEL
ERANGKKYYVTAVDQVKPKIALLKFVDKDPK
A.3 - E4rGel (anti-EGFR Fn3 - recombinant gelonin)
ISEFASVSDVPRDLEVVAATPTSLLISWYHPFYYVAHSYRITYGETGGNSPVQEFT
VPRSPWFATISGLKPGVDYTITVYAVTDSNGSHPISINYRTEIDKPSQGSGGGGSG
LDTVSFSTKGATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCFVLVAL
SNDNGQLAEIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLHFG
GSYPSLEGEKAYRETTDLGIEPLRIGIKKLDENAIDNYKPTEIASSLLVVIQMVSE
AARFTFIENQIRNNFQQRIRPANNTISLENKWGKLSFQIRTSGANGMFSEAVELE
RANGKKYYVTAVDQVKPKIALLKFVDKDPK
A.4 - 3ErGel (anti-CEA ds-scFv - recombinant gelonin)
AMADIEFASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQC
LEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNE
GTPTGPYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSVSVG
DRVTIACSASSSVPYMHWLQQKPGKSPKLLIYLTSNLASGVPSRFSGSGSGTDYS
LTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSSRVDGGGGSGGGGSL
QGLDTVSFSTKGATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCFVL
VALSNDNGQLAEIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLH
FGGSYPSLEGEKAYRETTDLGIEPLRIGIKKLDENAIDNYKPTEIASSLLVVIQMV
SEAARFTFIENQIRNNFQQRIRPANNTISLENKWGKLSFQIRTSGANGMFSEAVE
LERANGKKYYVTAVDQVKPKIALLKFVDKDPK
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A.5 - FErGel (anti-CEA ds-scFv - recombinant gelonin)
AMADIEFASQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQC
LEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNE
GTPTGPYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSENVLTQSPSSMSASVG
DRVTIACSASSSVPYMHWFQQKPGKSPKLLIYSTSNLASGVPSRFSGSGSGTDYS
LTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKAAAGSGGGGSGLDTVSFSTK
GATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCFVLVALSNDNGQLA
EIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLHFGGSYPSLEGE
KAYRETTDLGIEPLRIGIKKLDENAIDNYKPTEIASSLLVVIQMVSEAARFTFIEN
QIRNNFQQRIRPANNTISLENKWGKLSFQIRTSGANGMFSEAVELERANGKKYY
VTAVDQVKPKIALLKFVDKDPK
Chapter 3
A.6 - C7LLO (anti-CEA Fn3 - listeriolysin 0)
ISEFASVSDGTLSRDLGVVAATPTSLLISWYYSYSHHYSSYRITYGETGGNSPVQE
FTVPRYRAFATISGLKPGVDYTITVYAVTSSSSYSYPISINYRTEIDKPSQGSGGGG
SKKIMLVFITLILVSLPIAQQTEAKDASAFNKENLISSMAPPASPPASPKTPIEKKH
ADEIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQ
NNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQD
NKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPNVSAKIDYDDEMAYSESQLI
AKFGTAFKAVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGK
AVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGK
SVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPG
VPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEI
NYDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEW
WRTVIDDRNLPLVKNRNISIWGTTLYPKYSNSVDNPIE
A.7 - E6LLO (anti-EGFR Fn3 - listeriolysin 0)
ISEFASVSDVPRDLEVVAATPTSLLISWFDYAVTYYRITYGETGGNSPVQEFTVPG
WISTATISGLKPGVDYTITVYAVTDNSRWPFRSTPISINYRTEIDKPSQGSGGGGS
KKIMLVFITLILVSLPIAQQTEAKDASAFNKENLISSMAPPASPPASPKTPIEKKH
ADEIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQ
NNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQD
NKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPNVSAKIDYDDEMAYSESQLI
AKFGTAFKAVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGK
AVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGK
SVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPG
VPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEI
NYDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEW
WRTVIDDRNLPLVKNRNISIWGTTLYPKYSNSVDNPIE
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A.8 - C7PFO (anti-CEA Fn3 - perfringolysin 0)
SASVSDGTLSRDLGVVAATPTSLLISWYYSYSHHYSSYRITYGETGGNSPVQEFTV
PRYRAFATISGLKPGVDYTITVYAVTSSSSYSYPISINYRTEIDKPSQGSGGGGSSS
KDITDKNQSIDSGISSLSYNRNEVLASNGDKIESFVPKEGKKAGNKFIVVERQKR
SLTTSPVDISIIDSVNDRTYPGALQLADKAFVENRPTILMVKRKPININIDLPGLK
GENSIKVDDPTYGKVSGAIDELVSKWNEKYSSTHTLPARTQYSESMVYSKSQISS
ALNVNAKVLENSLGVDFNAVANNEKKVMILAYKQIFYTVSADLPKNPSDLFDDS
VTFNDLKQKGVSNEAPPLMVSNVAYGRTIYVKLETTSSSKDVQAAFKALIKNTDI
KNSQQYKDIYENSSFTAVVLGGDAQEHNKVVTKDFDEIRKVIKDNATFSTKNPA
YPISYTSVFLKDNSVAAVHNKTDYIETTSTEYSKGKINLDHSGAYVAQFEVAWDE
VSYDKEGNEVLTHKTWDGNYQDKTAHYSTVIPLEANARNIRIKAREATGLAWE
WWRDVISEYDVPLTNNINVSIWGTTLYPGSSITYNGSHHHHHH
A.9 - E6PFO (anti-EGFR Fn3 - perfringolysin 0)
SASVSDVPRDLEVVAATPTSLLISWFDYAVTYYRITYGETGGNSPVQEFTVPGWI
STATISGLKPGVDYTITVYAVTDNSRWPFRSTPISINYRTEIDKPSQGSGGGGSSS
KDITDKNQSIDSGISSLSYNRNEVLASNGDKIESFVPKEGKKAGNKFIVVERQKR
SLTTSPVDISIIDSVNDRTYPGALQLADKAFVENRPTILMVKRKPININIDLPGLK
GENSIKVDDPTYGKVSGAIDELVSKWNEKYSSTHTLPARTQYSESMVYSKSQISS
ALNVNAKVLENSLGVDFNAVANNEKKVMILAYKQIFYTVSADLPKNPSDLFDDS
VTFNDLKQKGVSNEAPPLMVSNVAYGRTIYVKLETTSSSKDVQAAFKALIKNTDI
KNSQQYKDIYENSSFTAVVLGGDAQEHNKVVTKDFDEIRKVIKDNATFSTKNPA
YPISYTSVFLKDNSVAAVHNKTDYIETTSTEYSKGKINLDHSGAYVAQFEVAWDE
VSYDKEGNEVLTHKTWDGNYQDKTAHYSTVIPLEANARNIRIKAREATGLAWE
WWRDVISEYDVPLTNNINVSIWGTTLYPGSSITYNGSHHHHHH
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Appendix B - Alternative approaches to targeted intracellular delivery
Introduction
The field of intracellular delivery is rife with tools designed to selectively
permeabilize subcellular compartments without cytotoxic effects. Substantial
research efforts have been devoted to the advancement of delivery tools derived
from small molecules (1), lipids (2), or polymers (3-5). But as alluded to earlier in
this work (Chapters 2 & 3), one of the keys to success in this area is the ability to
target that delivery.
Small molecules are probably the easiest of the intracellular delivery tools to
target. Much like the recently popularized antibody drug conjugate technologies (6,
7), small molecules like monensin, chloroquine, or retinoic acid can be amenable to
chemical conjugation to an antibody to direct their release inside a specific cell type.
The same methodology can also be applied to conjugation of lipids (8) or polymers
(9).
We set out to develop a tool for mediating targeted, in trans, intracellular
biotherapeutic delivery. In doing so, we took an open minded approach as to which
membrane active molecules might be most easily targeted using our lab's antigen
binding protein scaffolds. Here we describe the various conjugates and fusion
proteins we produced that showed only limited, or a total lack, of potentiating
activity in our immunotoxin model system. And while this should not be taken as
strict indictment of these active molecules, we believe to have learned a bit about
the importance of potency in any targeting effort.
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Methods
PA MAM den drimer conjugation & purification
Poly-amidoamine dedrimers are branched polymers containing a combination of
primary and tertiary amines which serve destabilize membranes by direct
interaction or by buffering endosomal acidification, respectively (10, 11). Dan
Bonner of the Hammond Lab at MIT kindly provided functionalized generation 4 or
5 dendrimers for conjugation and testing (12). These dendrimers were built on a
disulfide-bonded, bifunctional initiator that was reduced to expose free sulfhydryl
groups for reaction with maleimide groups at the end of poly(ethylene glycol) chains
conjugated to anti-CEA and anti-EGFR IgG (sm3E and 225).
Prior work conducted under this same collaboration revealed that naive
dendrimer shows high levels of non-specific cytotoxicity specific to primary amine
membrane interaction. Thus, for many conjugations, we used dendrimers with
primary amines capped by acetylation to varying degrees, usually 50%.
IgG-dendrimer conjugates were purified using Protein A - Agarose resin
(Thermo Scientific) and were characterized qualitatively by SDS-PAGE. Binding
was assayed by flow cytometry on fixed, antigen-positive cells labeled with a
fluorophore conjugated secondary antibody against the Fc domain of the dendrimer
conjugated IgG. Cytotoxicity of dendrimer conjugates alone or in the presence of
gelonin immunotoxins was assessed as described previously (Chapter 2)
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Targeted fusion peptide construction & synthesis
In nature, viruses have evolved some of the most efficient mechanisms for
intracellular delivery. Part of that success is built upon small fusogenic peptides
whose ability to mediate intracellular delivery in other settings is recognized (13).
Other have used peptides directly fused or conjugated to an active molecule to
mediate delivery (14-16) and Wadia et aL. were able to mediate in trans
intracellular delivery of cre recombinase using TAT peptide as an internalization
mechanism (17).
We hoped to mimic this result in a targeted manner using our engineered
Fn3 domains with either N-terminal or C-terminal fusions to the peptides.
Specifically, we chose to test the hemaglutinin (HA), gp4l (GP), flavivirus (Dengue
- DN), and leucine zipper (LZ) peptides (Table B.1) for targeted potentiator activity.
Using the overlap-extension PCR method described by Geiser et a]. (18) we inserted
codon optimized sequences encoding the aforementioned peptides either 5' or 3' of
engineered Fn3 sequences in a pET24b derived vector.
Table B.1 - Fusogenic peptides tested for targeted membrane disruption.
Peptide (Abbreviation) Sqec eeec
Hemaglutinin (H A) GLFGAIAGFIENGWEG (19)
gp41 (GP) GVFVLGFLGFLATAGS (19)
Flavivirus (DN) DRGWGNGCGLFGKGSL (20)
Leuine Zipper (LZ) ALEALAEALEALAEALA (21)
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Fn3's designed with fusogenic peptide arms were synthesized and purified as
described previously (22) and their characterization in our model system was
conducted in the same manner as for the other potentiators.
Other potentiators tested for in trans delivery activity
In addition to the agents described above for targeted potentiation we also tested a
number of other small molecules, peptides, and polymers for in trans delivery
capabilities in the absence of any targeting modality. These included the synthetic
peptide INF7 (GLFEAIEGFIENGWEGMIDGWY - AnaSpec, Fremont, CA) (23), a
poly(propyl-acrylic acid)-b-(butyl-methacrylate-co-pyrridyl-disulfide methacrylate)
polymer kindly donated by the Stayton Lab (University of Washington, Seattle, WA)
(9), stapled peptides generously provided by the Verdine Lab (Harvard University,
Cambridge, MA) (24), poly(ethylenimine) (25), retinoic acid (Sigma-Aldrich) (1), and
chloroquine (Sigma-Aldrich) (26).
Results
IgG-G5 Testing
Antibodies targeting either CEA (sm3E) or EGFR (225) were conjugated to G5
dendrimer hemispheres with 50% of their primary amines acetylated (G5Ac5O)
through bifunctional NHS-PEG-Maleimide. In these reactions, protein was used as
the limiting reagent whose subsequent yield was quite high, but a strong excess of
~40% molar was used of the G5Ac5O. SDS-PAGE of the Protein A purified IgG's
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showed stepped bands that we hypothesize are representative of additional G5Ac5O
reactions (Figure B.1)
These conjugates conferred modest independent cytotoxicity and some signs
of synergy, but their combined effects appear mostly additive (Figure B.2A/B)
1 2 3 4 5 6
Figure B.1 - IgG-G5Ac5O characterization. Reducing SDS-PAGE was run with
ColorPlus Prestained Protein Ladder (New England Biolabs, Ipswich, MA) (lane 1),
225 mAb (lane 2), protein A-agarose resin flow through from a 225/G5Ac5O reaction
(lane 3) and a sm3E/G5Ac5O reaction (lane 4), the protein A-agarose resin purified
225-G5Ac5O (lane 5) and purified sm3E-G5Ac5O (lane 6). The protein ladder MW's
from top to bottom are 150 kDa (barely visible), 100, 80, 60, 50, 40, 30, 25, and 20.
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Figure B.2 - Cytotoxicity of IgG-G5Ac50 conjugate. (A) The EGFR-overexpressing
cell line A431 is titrated with untargeted gelonin, 225-G5Ac5O, and their
combination titrated together. (B) HT-1080(CEA) over expressing CEA is titrated
with untargeted gelonin, sm3E-G5Ac5O, and their combination titrated together.
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Targeted fusogenic peptide testing
Fusogenic peptides HA, GP, DN, and LZ were incorporated at either the N-terminus
or C-terminus of CEA or EGFR targeted Fn3's depending on any perceived necessity
for N-terminal exposure for activity. Consistent with their own independent
expression levels, peptides fused to CEA-binding C743 (C7) were expressed at lower
soluble levels, < 1 mg/L, than peptides fused to EGFR-binding E246 (E4) whose
expression levels were around 5 mg/L.
We assayed targeted fusogenic peptides independent cytotoxicity and in
combination with untargeted gelonin at levels where we might expect to see activity
from both components. Example data are shown for various combinations of
peptide and targeting Fn3. In some cases the targeted peptides show no
independent cytotoxicity (Figure B.3A) and in those cases we didn't expect to see
any synergistic activity with gelonin since at some level endosomal disruption
should induce cytotoxicity or correlate with general membrane disruption. But even
for those examples in which independent cytotoxicity was observed (Figure B.3B)
there were no signs of synergy with gelonin.
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Figure B.3 - Targeted fusogenic peptide cytotoxicity. (A) EGFR-overexpressing
A431 cells were treated with varying concentrations of GPE4 or E4DN in the
presence or absence of a fixed, moderately cytotoxic concentration of non-
competitively EGFR-targeted gelonin immunotoxin (E6rGel). (B) CEA-
overexpressing HT-1080(CEA) cells were titrated with gelonin, HAC7, C7LZ, or a
combination thereof.
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Un targeted potentiator testing
Poly(propyl-acrylic acid) (PAAc) copolymer provided by the Stayton Lab and
commercially obtained INF7 peptide showed modest enhancement of cytotoxicity
when added to titrations of untargeted gelonin (Figure B.4). However when the
roles were reversed (i.e. polymer or peptide titration with fixed, non-toxic
concentration of gelonin) no potentiation was observed (data not shown). Attempts
to conjugate PAAc polymer samples to Fn3 or IgG targeting proteins using Traut's
reagent and disulfide bond formation with pyridyl groups were largely unsuccessful
in our hands.
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Figure B.4 - Potentiation of rGel cytotoxicity by polymer and synthetic peptide.
Fixed concentrations of polymer or peptide were added to titrations of rGel on HT-
1080 cells.
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Stapled peptides given to us by the Verdine Lab showed additive cytotoxic
effects when added at fixed concentrations to CEA-targeted gelonin immunotoxin
titrations (Figure B.5A). They also were cytotoxic in their own right when titrated
to concentrations above 1 gM (Figure B.5B).
-C7rGeI
-@-+5uM S1-113
-O-+lOuM FS1
-@-+lOuM S1-23
1.E-10 1.E-09 1.E-08
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Figure B. 5- Additive and independent cytotoxicity of stapled peptides. (A) Stapled
peptides are additive in their cytotoxicity when combined with CEA-targeted
immunotoxin, but are also (B) independently cytotoxic at concentrations above one
micromolar.
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Small molecule enhancers were also tested for potentiating activity. We
tested poly(ethylenimine) (PEI), chloroquine, and retinoic acid for independent
cytotoxicity (Figure B.6A) finding that at 10 gM or higher, these molecules could
induce cell death. When added to titrations of gelonin at non-toxic concentrations,
only PEI and retinoic acid conferred even modest enhancement of cytotoxicity
(Figure B.6B).
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Figure B.6 - Small molecule potentiator cytotoxicity. (A) Independent cytotoxicity
of small molecule potentiators. (B) Non-toxic concentrations of small molecules
added to titrations of untargeted gelonin.
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Discussion
Each of the different membrane active agents tested here has been implicated by
others as such. However, in our hands and in our system they were not able to
strongly potentiate the cytotoxic activity of either untargeted gelonin or gelonin
immunotoxins. These data are supported by the fact that delivery mechanisms
involving these molecules haven't progressed clinically. But this should not
discourage others from attempting to target these molecules. If enough PAAc
chains were conjugated to an appropriate targeting agent, then the binding and
internalization of that agent might serve to increase the endosomal concentration of
PAAc to active levels.
What is more important to take away from these experiments is the
criticality of potency. Even if one of these molecules was capable of potentiating
immunotoxin activity, if it did so only at a very high concentration, then it would be
difficult to achieve the same type of activity in a targeted manner, the true goal of
this work. If an average endosome has a diameter of 100 nm, then its volume is
4.2x10-18 L, and there would need to be -25 molecules of an agent active at 10 gM to
disrupt it. This same endosome, assuming it samples the cell membrane randomly
and that antigen is distributed over that membrane randomly at -105 copies per
cell, will contain -10 antigens. Such that even when saturating antigen with
binding proteins, which is difficult to accomplish in vivo, those proteins would have
to be decorated with > 2.5 active molecules each. This degree of labeling is not
unrealistic, especially for IgG size proteins, but saturation can be hard to achieve.
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Appendix C - Modeling cytotoxic synergy
Introduction
Our efforts in assessing the potentiating activity of membrane disruptive agents led
us to question under what conditions that activity might be most easily observed.
We hoped to inform the design of in vitro cytotoxicity experiments used for initial
screening of different potentiators. Classically, simultaneous titration of both
agents at a fixed molar ratio would be used (1, 2). But data collected in this way
often requires statistical analysis to parse out synergistic interactions. We desired
an approach where synergy might be more readily interpreted.
Methods
Equations defining cell viability and IC5 o were derived from those of Chou and
Talalay (1). The first equation gives the general definition of the combination index
(CI) metric for two different drugs, Di and D 2 :
C (D) 1 + (D) 2 + (D)1(D)2
(Dx)1 (Dx)2 (DX) 1,2
where, D. is a concentration for a fraction affected x, such as IC5 o and:
CI(- (ah,2 1- (fu)1,2
(fu)1,2 (fu)1,2
where fa and fu are the fraction affected and unaffected, respectively. Conveniently,
fu is directly quatified in our cytotoxicity assays. If we assume that the active
concentrations of Di and D2 are significantly different, then the right most term of
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the CI definition is small compared to the other two terms. If we choose to ignore it
completely and focus on a 50% fraction affected then:
1-V D D2
V (D5 0 ) 1  (D 5 0) 2
where V is the viability (as a fraction). We can rearrage this equation and consider
immunotoxin (IT) and potentiator (P) as Di and D2 respectively to get a direct
percent viability output to relate to our assays as:
V -
1+ [I]+ ]IT 5 0 P50
This equation will define our combination cytotoxicity, but in order to address the
affect of synergy, if any, on our cytotoxicity measurement then it will have to be
incorporated into the equation as an influence of P on IT5o. Without a clear
mechanistic way to define such an interaction, we arbitrarily selected a modified
hyperbolic dose-effect curve shape:
IT5 0  IT5 0
1+ _X k X kdis
KD,P koff kdeg
Here, IT50 is dependent on KD,P, the affinity of potentiator for a surface antigen, ki /
koff the relative rate of internalization of the potentiator and antigen versus the
antigen binding off-rate, and kais / kdeg the relative rate of endosomal disruption
versus potentiator degradation. Parameter values were based on in vitro data or
values understood to be reasonable from the literature. (Table C.1)
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Table B.1 - Cytotoxic potentiation model parameters
Parameter Value
IT-s
Pso0
2x10 4 M
5x10 7 M
0/10-0 - 10-7 M
5x10-9
2x10 s
2x10~6
5x10-7
3x10-5
Results
A simulation was run using the parameters outlined above and the viability levels
under each treatment concentration combination were output first for an
assumption of only additive cytotoxic interactions (Figure C.1).
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Figure C.1 - Additive cytotoxicity of immunotoxin and potentiator. Concentration
dependent loss of viability is resolved across two therapeutic dimensions under
conditions of no interaction between them.
Subsequently we interrogated the same loss of viability when factoring in the
potentiative reduction of the IC5o of the immunotoxin. Using the modified
hyperbolic dose-response equation to determine the affect of potentiator, we looked
at the same range of concentrations for immunotoxin or potentiator for synergistic
effects on viability (Figure C.2).
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Figure C.2 Synergistic loss of viability. When potentiator affects the IC50 of the
immunotoxins there is a general reduction of viability across the screened two-
dimensional concentration space.
Then to understand how to best observe the difference between putative
potentiators that are either synergistic or merely additive, we simply subtracted the
synergistic viability from the additive viability to understand the differential
viability (Figure C.3).
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Figure C.3 - Differential viability. Synergistic viability is subtracted from additive
viability across the range of concentrations for both species.
Discussion
When testing for synergistic activity between two therapeutic agents there are
different statistical methods that can be applied to better understand the character
of their interaction and it's strength (1-3). But sometimes, especially when
searching a large number of potentiating candidates, it is valuable to be able to
characterize synergy without having to calculate it. This rudimentary cytotoxicity
model suggests that it should be possible to easily and directly observe potentiation
from titrating a potentiator against a fixed, almost non-toxic concentration of
immunotoxin. For such a titration through the concentration space, the differential
viability is maximized.
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